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Summary and Conclusions 
Lymphatic filariasis is primarily a disease of the poor because of its 
prevalence in remote rural areas and in disfavored peri-urban and urban 
areas. LF is caused by nematode parasite species Wuchereria bancrofti, 
Brugia malayi and B. timori. It is transmitted through mosquitoes. 
Globally, LF is thought to be second leading cause of permanent and long 
term disability. Some 120 million people are infected worldwide, and the 
disease is endemic in more than 80 countries and territories. More than 
90% of cases with W. bancrofti and 10% of cases with B. malayi are 
recorded. The spectrum of lymphatic filariasis is analogous to leprosy. 
Microfilaria carriers with no signs and symptoms represent one pole and 
patients with elephantiasis and chronic lesions represent the other pole. 
Several strategies are currently being tried for control and eradication of 
filariasis but the main emphasis continues to be on vector control and 
chemotherapy. DEC, IVM and ALB are the antifilarials used in 
chemotherapy. Recently, the World Health Organization (WHO) in 
collaboration with GlaxoSmithKline launched a global LF elimination 
program with a drug combination approach consisting of treatment 
schedules with ALB + DEC or IVM. However, the most intriguing feature 
of the infection is its unpredictable recurrence after treatment. The reasons 
for this are not clear. For instance, it is not known whether a) the altered 
immune responses of the host following treatment with antifilarial(s) are 
able to provide conducive environment for re-infection, b) individuals 
become more vulnerable to acquiring infection or become resistant to re-
infection after a course or repeated courses of treatment, and c) prior 
exposure to antifilarial(s) alter the biology/infectivity of parasite. 
Unfortunately there have been no systematic studies to answer these 
questions. The present study was therefore, aimed at investigating 
alterations in immune responses of the B. malayi-miQcXtd host after 
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treatment with antifilarials and after re-infection of the treated host. This 
will help understanding the possible reasons involved in the recurrence of 
infection or resistance to therapy in human filariasis. 
The present study was carried out using M. coucha-B. malayi model 
comprising the main groups (Table as below): infected animals, infected 
treated animals, infected treated re-infected animals, infected re-infected 
and age and sex matched normal infected animals to see the effect of re-
infection in antifilarial treated animals on the modulation of acquired 
immunity with particular reference to parasitological, physiological and 
immunological responses of the host. 
Selection and grouping of animals 
Group 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
No. of animals 
16 
8 
8 
8 
16 
8 
8 
8 
Animals 
Infected (Inf) 
Infected Treated (Inf-T) 
Infected Treated-Reinfected (InfT-R) 
Infected-Reinfected (Inf-R) 
Normal (N) 
Normal-Treated (N-T) 
Normal Treated Infected (NT-I) 
Normal-infected (N-I) 
DEC at 150 mg citrate/kg or ALB at 50 mg / kg were given through i.p. 
and s.c. route, respectively. The agents were administered five consecutive 
days. Fresh solution was prepared daily before administration. 
Infected or normal treated animals were exposed to L3 on day 30 since the 
start of the treatment. 
Various parameters like parasitological, blood cell counts and 
immunological (humoral, cell proliferation and cytokines) responses of the 
host before treatment, one month post-treatment and one-month post-
larval (L3) inoculation (= two month post-treatment) were carried out. 
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The antibody response of pre- and post-DEC/ALB treated and 
subsequently re-infected animal sera samples were analyzed qualitatively 
with western blot of BmA and BmMf and Sephadex G-200 
chromatographic fractions of BmA. Experiments were also carried out to 
correlate DNA integrity using comet assay of lymph node and spleen cells 
of M. coucha harbouring early, mid and chronic stages of B. malayi 
infection and cell proliferative response to filarial antigen and mitogen of 
the host. 
The salient findings of the present study are as follows: 
In contrast to control animals (Inf) a marked reduction in Mf count (80%) 
was found in Inf-T animals on day 7 since the start of the treatment, which 
thereafter remained suppressed till the day of sacrifice. The level of 
microfilaraemia in InfT-R animals increased within a week after challenge 
with L3, and crossed the pre-treatment level by day 63. However, the level 
of Mf in Inf-R animals did not increase and remained comparable with the 
pre-treatment level throughout the observation period. 
DEC treatment failed to kill adult worms. The percent recovery of 
developing stages of larvae from InfT-R animals was higher as compared 
to their counterparts Inf-R and N-I animals indicating that DEC treatment 
might be responsible for such enhancement in worm recovery. 
An inverse correlation between microfilaraemia and eosinophilia was 
found. Decrease in eosinophil counts was accompanied by removal of Mf 
from the circulation. 
Treatment with DEC in Inf-T animals caused increase in IgG levels 
directed against BmA, BmA-I and BmMf of which anti-BmA antibody 
levels remained almost unchanged till the day of sacrifice. In InfT-R 
animals the anti BmA and anti-BmMf-I antibody levels were comparable 
to levels of Inf-T animals, whereas in the Inf-R group, anti-BmA-I and 
Summary and Conclusions 
BmMf IgG levels increased and the IgG levels against rest of parasite 
preparations decreased significantly. 
Treatment with DEC did not alter the anti-BmA, anti-BmA-I, BmMf and 
BmMf-I IgM levels in any of the animals except age and sex matched 
animals of group N-I. 
Treatment restored the proliferative response of cells of infected animals 
to Con-A and BmA-I, which however suppressed after reinfection. 
While DEC treatment in infected animals caused decrease in BmA and 
LPS stimulated IL-6 production, TNF-a production was found to be 
increased. In InfT-R animals BmA induced IL-6 production was further 
decreased but no further increase in the level of BmA induced TNF-a 
production was observed in these animals. In contrast LPS stimulated cells 
produced significant increase in TNF-a production. 
DEC treatment caused decrease in BmA induced IL-10 production in Inf 
animals. In InfT-R it further decreased. BmA induced IFN-y production 
was increased after treatment, which was again increased (more than 3 
times) after re-infection. 
Treatment with ALB in Inf animals resulted complete clearance of 
microfilaraemia and worms. Interestingly neither InfT-R nor NT-I animals 
showed developing stages of the parasites indicating prophylactic potential 
of ALB. 
The decrease in eosinophil counts in response to ALB treatment was less 
as compared to the effect of DEC. Re-infection in treated animals failed to 
increase the TLC and eosinophil counts. 
Treatment with ALB caused significant and gradual decrease in IgG 
directed against BmA, BmA-I, BmMf and BmMf-I till the day of sacrifice. 
Re-exposure with L3 in treated animals (InfT-R) caused fiirther decrease in 
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anti-BmA, BmMf, BmMf-I IgG levels. In Inf-R animals, IgG levels 
increased significantly as compared to InfT-R animals. 
Treatment with ALB showed significant decrease in IgM levels directed 
against BmA, BmMf and BmMf-I in infected animals. Re-exposure of 
infscted treated animals (InfT-R) caused significant decrease in anti- BmA 
and BmMf-I IgM antibody levels. However levels of anti-BmA-I and anti-
BmMf IgM in InfT-R animals remained unaltered compared to Inf-T. 
Inf-R animals showed increase in anti-BmA and anti-BmMf-I IgM 
antibodies. 
Like DEC, ALB also restored the proliferative response of both lymph 
node and splenocytes to all the stimulants, although the response towards 
Con-A was significantly high. Re-infection failed to further alter the 
proliferative response of the spleen cells or lymph node cells to the 
stimulants when compared with Inf-T group. Interestingly, cells of Inf-R 
animals showed significantly decreased proliferative responses to the 
stimulants. 
ALB treatment caused significant increase in IL-6 production in infected 
animals. However in InfT-R animals the IL-6 production was decreased 
when compared with value obtained in Inf-T animals but is comparable to 
the level of Inf animals. 
Treatment (ALB) did not affect the TNF-a production in infected animals 
but in InfT-R animals the production decreased. 
IFN-y production in ALB treated (Inf-T) animals was upregulated 
significantly, which however decreased after re-exposure (InfT-R 
animals). 
ALB treatment caused increased IL-10 production in Inf animals. 
However in InfT-R animals the level of BmA stimulated IL-10 production 
remained almost same when compared with Inf animals. 
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In Inf-R animals, BmA stimulated IL-6 and TNF-a production was 
comparable to Inf animals. Whereas re-infection up-regulated BmA 
stimulated IFN-y production in infected (Inf) animals, BmA stimulated IL-
10 production was found to be decreased. 
The present findings on the effects of DEC in B. malayi infected M 
concha are in accordance with the reported observations in bancroflian 
patients treated with DEC. The following are the inferences made from the 
above results of the present study. Firstly, since Th2 cells produce IL-4 
and IL-10, which were reported to facilitate parasite survival and that the 
magnitude of response correlates with the severity of disease, the increase 
in IL-10 observed in InfT-R group in the present study clearly 
demonstrates that DEC treatment prior to re-infection facilitates the 
'take'/establishment of the infection. Second, a quantitative relationship 
between the raised TNF-a levels and the development of re-infection was 
demonstrated for the infected or infected treated animals. Third, while 
DEC decreased IL-10 production, ALB elevated IL-10 production. This 
suggests that the adult antigens available after ALB induced adult parasite 
killing, stimulate IL-10 production. This is fiirther supported by the 
observation that IL-10 production is not stimulated by DEC treatment 
since DEC is not an efficient adulticidal agent. Fourth, IL-6, TNF-a and 
IFN-y increased significantly after treatment with DEC in normal 
uninfected animals while IL-10 remained decreased. The significance of 
this observation to establishment of or resistance to re-infection is not 
readily evident, but the effect is clearly a direct effect of DEC rather than 
DEC 'opsonized' parasite antigen effect since no antigen is available in 
these animals. Fifth, apparently elevated levels of IFN-y in re-infected 
animals correlated with the lesser number of the parasite establishment. 
This finding is in contrast to DEC treatment in infected animals, which 
facilitated the development of re-inoculated L3 as evidenced by 
development of more number of parasites. 
Summary and Conclusions 
Sera of infected DEC treated animals reacted with a lesser number of 
bands of BmA and BmA-I. The range of reactive bands increased after re-
infection showing strong reactivity with 32 and 45 kDa molecules of ether 
BmA and or BmA-I. Though Inf-R sera also identified lesser number of 
bands they reacted strongly with 22 and 28 kDa molecules of BmA and or 
BmA-II. 
Sera of all the categories of animals reacted either moderately or weakly 
with 38 kDa and below of BmA-II antigen. 
Sera from Inf-T animals (ALB treatment) reacted with 6.8 - > 160 kDa 
BmA antigen molecules. InfT-R sera reacted strongly with 62 kDa 
molecule of BmA and BmA-I was strongly reactive. 
Sera of Inf-R animals reacted strongly with 22 and 28 kDa molecules of 
BmA. 
The level of DNA damage in the splenocytes and lymphocytes of M. 
coucha (uninfected and B. malayi infected) was assessed on the basis of 
migration of DNA. The chronically infected animals showed DNA 
damage in both splenocytes and lymphocytes, however, 75% of animals 
harbouring mid stage of infection with Mf in the peripheral blood showed 
substantially low damage in DNA of splenocytes only. Interestingly, 
animals of early stage of infection with no peripheral Mf showed no 
damage in DNA of splenocytes or lymphocytes. Apparently there was a 
direct correlation between extent of DNA damage and duration of 
exposure of infection. Further DNA damage appeared to be correlated 
with the proliferative response of splenocytes or lymphocytes of animals 
to filarial extract and mitogen. 
Thus from the present study it is concluded that 
In ALB treated and reinfected animals, increased the BmA specific CMI, 
which may be correlated with absence of (resistance to) re-infection. 
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• Slow and gradual decrease in filarial specific IgG in ALB treated (Inf-T) 
and no further appearance of IgG after re-infection correlated with the 
absence of re-infection. 
• A prompt increase in filarial specific IgG in infected DEC treated (Inf-T) 
animals and no further alteration in IgG levels but re-suppression in cell 
proliferation after re-infection supported by the presence of developing 
stages of re-infection. 
• Whereas 62 kDa band recognized by sera of ALB treated reinfected 
animals was correlated with development of resistance against re-
infection, 32 and 45 kDa bands recognized by sera of DEC treated 
reinfected animals correlated with the development of re-infection. 
However, 22 and 28 kDa bands were identified with sera of Inf-R animals, 
which showed establishment of lesser number of worms. These antigens 
may be important for development of strategies for treatment/control 
modalities of the disease. 
• DNA damage in splenocytes/lymphocytes of animals harbouring chronic 
stage of B. malayi infection correlated hyporesponsiveness of cellular 
proliferative response of the host. 
Thus the results of the present study indicate that while ALB treatment 
may facilitate development of resistance against re-infection, DEC 
treatment may enhance recurrence of infection. 
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Introduction 
Filariasis, which is synonymous to elephantiasisis, is one of the oldest 
diseases known to mankind since 6th century B.C. It is prevalent in many 
parts of the tropics and sub-tropics of the world. It comprises several 
diseases caused by nematode parasites, of which the most common are 
lymphatic filariasis and onchocerciasis. The lymphatic filariasis (LF) is more 
prevalent of the two. Onchocerciasis occurs in about 20 million people in 
endemic areas of Africa, Central and South America and causes blindness in 
about one million. Onchocerciasis is transmitted through black flies. 
LF is a mosquito borne disease. It is the major cause of disability among the 
tropical infectious diseases and remains unresolved major public health 
problem in many parts of the tropics and sub-tropics of the world. It is 
caused by Wuchereria bancrofti, Brugia malayx and B. timori. Worldwide 
1100 million people are at risk £ind 78.6 million show microfilariae (Mf) or 
overt disease (Michael et al. 1996). Global estimates of LF reveals 
approximately 120 million people with Wuchereria bancrofti (90% of cases) 
and with Brugia malayi (10% of cases) are affected, with one billion people 
considered to be at risk of becoming infected (Michael et al. 1996). 
Bancrofti an filariasis is prevalent throughout the tropics whereas the brugian 
infection is confined to certain parts of India and South East Asia. Co-
existence of both brugian and bancroftian infections are reported from 
certain parts of India like Kerala, South India. 
LI puts a tremendous strain on health care systems particularly related to 
financial burden in endemic areas, especially since chronic disability afflicts 
individuals during their most productive years. It is estimated that medical 
treatment for acute and chronic manifestation of the disease costs millions of 
dollars each year across the endemic regions. In India alone over 10 million 
people per year seek treatment for LF and treatment costs which includes 
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people per year seek treatment for LF and treatment costs which includes 
expenditure on medicines, doctors fees, travel, companion costs and 
accommodation exceed 30 million dollars per annum. These account 32% of 
individual's house hold expenses. It is also thought that the measurable 
health care costs of treating LF are small in proportion to the individual and 
societal costs from lost productivity. In addition to its economic impact, the 
clinical manifestations of LF impose a significant social burden on their 
sufferers. In such situation psychiatric counseling is often required. 
In India, filariasis has been recognized as a disease of National importance 
because of continuous spread of the disease causing sufferings and 
disability. Government of India launched National Filaria Control 
Programme (NFCP) in 1955. With an estimated population at risk of 454 
million in 261 districts and with 22.5 million individuals with filarial disease 
manifestations (14 million with hydrocele and 8.5 million with 
lymphoedema/ elephantiasis). Approximately 27 million people have 
asymptomatic microfilaraemia (WHO, 2002). In India, LF is caused by W. 
bancrofti and B. malayi. While W. bancrofti is transmitted through mosquito 
Culex quinquefasciatus, the vector of 5. malayi is Mansonia species. 
Clinical manifestations of bancroftian and brugian filariasis are very similar. 
However there are some basic differences in manifestations caused by two 
filariids. Though lymphoedema and elephantiasis of legs and arms are 
common to both but unlike bancroftian filariasis the absence of involvement 
in the genito-urinary organs is a characteristic feature of malayan filariasis. 
In endemic area there are categories of infected subjects, a) Asymptomatic 
amicrofilaraemics (endemic normal) - a major portion of the population 
shows no mf or clinical manifestations of filarial infection, b) Mf carriers -
10% to 20%) of individuals in the population show Mf in the peripheral 
blood but no recognizable clinical manifestations and some time they may 
remain as such for their whole life, c) Symptomatics -1.5%) of infected 
individuals shows clinical manifestations with or microfilaraemia. Thus 
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spectral of LF shows analogous with leprosy. One pole is represented by Mf 
carriers with no signs and symptoms and other pole by patients with 
elephantiasis and chronic lesions. 
Reduction of morbidity associated with the disease and interruption of 
transmission are the two general strategies currently being used in the 
control of human filariasis employing chemotherapy and vector control 
methods. Inspite of constant efforts to treat patient from free of infection 
some of the Mf carriers show reappearance of Mf after treatment with the 
main drug of choice for filariasis diethylcarbamazine citrate (DEC). 
Therefore, in view of re-infection control of LF has been a challenging 
problem. The main problem is with the limited understanding on aftermath 
of drug treatment on host-parasite relationship. Diethylcarbamazine (Hewitt 
et al. 1947) and Ivermectin (Campbell et al. 1983) are mainly 
microfilaricides with little or doubtful action on adult worms. DEC is taken 
by those who are infected with W. bancrofti whereas ivermectin is given for 
onchocerciasis or Loa loa patients concurrent with W. bancrofti. Inspite of 
repeated intake of the drug the infection is spreading very fast. Surveys 
carried out over the years have revealed that areas previously known to be 
free from filariasis show evidence of infection. These drugs are known to 
affect specific immune responses (Tyagi et al., 1986; Piessens et al., 1981; 
Haarbrink et. al., 1999) of the infected host. Despite a lot of work has been 
carried out on DEC its mode of action is still not completely understood. 
One of the handicaps in the management of filariasis by DEC is the 
profound immune hypo-responsiveness of the filaria-infected hosts. 
Immunological tolerance exists towards filarial antigens in the asymptomatic 
microfilaraemic carriers with decreased B-cell function (Nutman et al. 1987) 
and cellular responses (Piessens et al. 1980). However it has been reported 
that specific T-cell responsiveness can be partially recovered after treatment 
of microfilaraemics with DEC (Piessens et al 1981; Lammie et al., 1988b). 
In cross sectional studies besides microfilaraemics certain chronic cases with 
manifestations and endemic normals also showed T-cell unresponsiveness 
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indicating presence of active infection (Yazdanbakhsh et al. 1993). Animal 
models with lymphatic dwelling filarial infection also showed 
hyporesponsiveness as evident from filarial antigen specific cells with 
suppressor activity during microfilaraemic stage and late stage of infection 
(Lammie et al. 1984). However no studies have so far been made on the 
analysis of genetic material in lymphocytes of filaria infected hosts before 
and after antifilarial treatment 
Due to long-standing nature of the infection a constant stimulation is 
expected to alter the host system. In animal models atrophied lymph nodes 
are one of the characteristic features of chronicity of the infection. All these 
situations raise many questions, such as, to what extent the altered immune 
responses of the host following treatment with antifilarials are able provide 
environment for development of newly acquired infection. Whether 
individuals become more vulnerable to acquiring infection or become 
resistant to re-exposure to L3. Whether alteration in biology of parasite occur 
due to chemotherapy. Unfortunately, there have been no such studies 
pertaining to re-infection following chemotherapy. The major constraint 
faced towards this end has been primarily due to non-availability of suitable 
laboratory model, which can by and large simulate human situation. 
For W. bancrofti there is no permissive rodent host. The other human filarial 
parasite B. malayi which is easily transmittable to rodent host and several 
biological, biochemical, immunological, pathological etc. similarities with 
the W. bancrofti has been used for many manipulative research. M. coucha, 
a rodent model for B. malayi, developed and standardized (Murthy et al. 
1983) in this laboratory is not only a good laboratory model for various 
smdies (Murthy et al. 1990, 1995; Mishra, et al. 1997), its chemotherapeutic 
responses to DEC and IVM (Tyagi et al, 1986;) match with those reported 
for humans. Besides, routinely M. coucha-B. malayi model is being 
extensively used in this laboratory for investigation of various aspects of 
filariasis. If the alteration in immune response of the host induced by B. 
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responses are identified with relation to re-infection then the human 
responses to the parasites can be identified. Under these situations studies on 
this aspect was thought interesting and expected that it may provide valuable 
information for development of effective control of the disease. In view of 
the above importance in this aspect, the present study was aimed at 
investigating the response of re -exposure to B. malayi infected M coucha 
previously treated witli antifilarials. The objectives of the study were as 
follows: 
• 
• 
• 
• 
To study the development of infective stage of the parasite to adult 
worms and their fecundity after re-exposure to B. malayi infected M 
coucha previously treated with antifilarials. 
To investigate the specific immunological (humoral and cellular) and 
cytokine responses of the host after re-exposure to B. malayi infected 
M coucha previously treated with antifilarials. 
Identification of filarial antigen molecule with sera of antifilarial 
treated host and after re-exposure to B. malayi infected M. coucha 
previously treated with antifilarials. 
To investigate the DNA integrity in lymph node and spleen cells of M 
coucha harbouring different stages of 5. malayi. 
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2.1 Filariasis - One of the major tropical diseases 
2.1,1 Lymphatic filariasis: A major cause of morbidity in endemic areas 
Filariasis is a major public health problem of tropical and subtropical 
regions (Fig 1.1). It comprises a large group of parasitic infection caused by 
nematodes of the super family filarioidea. It represents a complex problem 
of major medical and social significance. Filarial worm can infect almost all 
vertebrates except fishes. But most of the parasite species are host specific. 
Of the several species only eight species infect man and of these 5 produces 
clinically distinguishable manifestations. (Table 1.1) 
Table 1.1 Common human filarial parasites: Geographical distribution and 
clinical syndrome 
Parasite 
Wucherena 
bancrofti 
Brugia malayi 
Brugia timori 
Onchocerca 
volvulus 
Loa loa 
Acanthocheilo 
nema perstans 
Acanthocheilo 
nema 
streptocercum 
Mansonella 
ozzardi 
Geographical 
distribution 
West Indies, 
North 
America 
Malaysia, 
India 
Indonesia 
Africa, 
Central 
America 
West& 
Central Africa 
Africa, South 
America 
Africa 
South 
America 
Vector 
Culex 
quinque-
fasciatas 
Mansonia sp 
Anopheles 
barbirostris 
Simulium sp 
Tanabid 
Culicoid sp 
Culicoid sp 
Cidicoid sp 
Seat of 
predilection 
Lymphatics 
Lymphatics 
Lymphatics 
Subcutaneous 
nodules 
Migrating 
cutaneous 
and 
subcutaneous 
tissues 
Body cavity 
Skin and 
Subcutaneous 
Body cavity 
Mf nature 
Blood and 
sheathed 
(nocturnal 
periodic) 
Blood and 
sheathed 
(periodic and 
sub-penodic) 
Blood and 
sheathed 
(nocturnal 
periodic 
Skin and 
unsheathed 
and non-
penodic 
Blood 
sheathed and 
diurnal 
periodic 
Blood 
unsheathed 
and non-
penodic 
Skin, non -
periodic and 
unsheathed 
Blood 
unsheathed 
and non 
periodic 
Common 
symptoms 
Elephantiasis 
Elephantiasis 
Adeno-
lymphangitis 
Dermatitis, 
River 
blindness, 
Skm nodules 
Calabar 
swelling 
Usually 
benign 
Benign 
Usually 
benign 
FS^ 
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Fig. 1.1 Geographical distributions of three major filarial species 
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Lymphatic tllariasis is caused by W. bancrofti and B. malayi and B. limori. Il 
is prevalent in tropical and subtropical regions of the world. Recent 
estimates showed that, 120 million people are affected with W. bancrofti 
(90%) and B. malayi (\Q%) (Michael et al, 1996). In India alone, about 454 
million people are exposed to the risk of lymphatic filarial infection. While 
about 27 million harbour Mf, 22.5 million suffer from clinical disease (14 
million with hydrocoele and 8.5 million with lymphoedema/ elephantiasis) 
(WHO, 2002). The disease is not fatal but manifestations lead to disability, 
disfigurement with pains, misery and impairment of health, which ultimately 
affect the economic burden of the country. In addition to its economic 
impact, the clinical manifestations both acute and chronic impose a 
significant social and psychological burden on their sufferers, often in their 
most productive stage of life (Fig. 1.3). 
2.1.1.1 Bancroftian filariasis 
Bancroftian filariasis caused by W. bancrofti is the most widely spread 
species among human filarial parasites. In India it is synonymous with 
elephantiasis. Description of typical elephantiasis appears in Susrutha 
Samhita, the epic treatise in surgery, written by renowned surgeon Susrutha 
in 6"^  century B.C. In 7* Century A.D. Madhava Karan described the signs 
and symptcms of filariasis in "Madhava Nidhan" which stands true even 
today. T. Clarke in 1709 described elephantiasis of legs in Cochin and 
called them Malabar leg. Although the symptoms were recognized long 
back the filarial parasites, the actual causative factor of bancroftian filariasis 
was discovered in 1863 by Demarquay in a patient's hydrocele fluid in 
Hawana, Cuba and in 1866 by Wucherer in the chylous urine in Brazil. In 
India, Lew-s identified Mf in the blood in 1872. In 1876, Bancroft 
discovered the adult female worm in lymphatic abscess of a Chinese patient 
and in 1888 Bowrne discovered the adult male worms. In the year 1875, 
Patrick Manson conceived for the first time idea that mosquitoes are the 
vectors of human fila'^iasis. He observed the nocturnal periodicity of Mf and 
in 1878 he was credited with the discovery of intermediate host, the 
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mosquito Culex pipens fatigans. The Bancroftian filarial parasite was 
named as W. bancrofti, since the Mf was discovered by Wucherer and the 
adult worm by Bancroft. The disease is endemic in India, Bangladesh, 
Burma, China, Indonesia, Malaysia, Papua New Guinea, The Philippines, 
SriLanka, Thailand, Vietnam, parts of East, Central and West Africa and 
Egypt, Madagascar and neighboring islands. The northern parts of South 
America, Brazil, parts of Central America, some Caribbean islands and 
many parts of the Pacific islands (WHO, 1987). In India except Jammu and 
Kashmir, all the states are endemic for bancroftian filariasis. 
2.1.1.2 Brugian filariasis 
Brugian filariasis is caused by the filarial parasites, B. malayi, B. timori. In 
1927 Lichtenstein and Brug discovered the B. malayi Mf in the blood smears 
of patients from Sumatra. Adult males and females were studied and 
described by Rao and Mapleston (1940) in India. The vectors are mosquitoes 
of genera Mansonia, Anopheles and Aedes. Brugian filariasis is most highly 
endemic in coastal areas of India and China (32% and 20% of the global 
burden, respectively). It is also prevalent in Indonesia, Malaysia, 
Philippines, Republic Korea, Thailand and Vietnam. B. timori is localized in 
lesser Sudan islands of Eastern Indonesia (WHO, 1987). 
2.2 Filarial parasite: Wuchereria bancrofti and Brugia malayi 
2.2.1 Morphology 
2.2.1.1 W. bancrofti 
(a) Adult Worms 
The adult worms live in lymph nodes and their channels. They are creamy-
white, minute thread like nematodes with a smooth cuticula. Both ends are 
tapering but bluntly rounded female measures 80 - 100 mm by 0.24 - 0.3 
mm the vulva is cervical in position. Short vagina and outer segment are 
single but the remaining genitalia are paired. The young embryos in the 
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inner portion of the uterus are confined within thin hyaline ovoidal shells. 
Outer portion of the uterus contains uncoiled embryos and known as Mf, 
which are ready to come out. A male measures about 40 mm in length by 0.1 
mm in diameter. Its caudal end is sharply curved. The copulatory spicules 
are distinctly unequal and dissimilar. 
(b) Microfilariae (Mf) 
Microfilariae are colourless and transparent covered with sheath. Body is 
organized into blunt head and pointed tail. It measures from 244 - 296 
micron in length by 7.5 - 10|Jm in diameter. In fixed and stained preparation 
a central column of nuclei are seen with landmarks. The landmarks consist 
of nerve ring, excretory pore, excretory cell, four 'G' cells and anal pore. 
(c) Infective larvae 
The mature infective larvae looks snake like which measures 1200 - 1600^m 
in length and 18 - 23|jni in diameter. It has well developed 3 caudal 
papillae. These are subequal in size. The anal ratio is about 4.5. 
2.2.1.2 B. malayi 
(a) Adult worms 
The adults of B. malayi bear a general resemblance to those of W. bancrofti; 
they are delicate, whitish, thread-like round worms, which are coiled up in 
pairs in delicate lymphatics. Mature females vary in length fi-om 43.5 - 55 
mm and in breadth fi^om 130 - 170 microns. The female vulva is survical in 
position and consists of a transverse slit. Cuticle is not smooth. Mature 
males vary in length fi-om 13.5 - 23.3 mm and in breadth from 70 to 80 
microns. The caudal part of male is coiled with 2 spicules (left long and 
right short) and at the tip of the tail; there are 4 - 6 small papillae. Mf are 
crowded together in coiled masses within the uterus and even in the vagina. 
The Mf are discharged into dwelling site and then escape into circulation 
(Fig. 1.5). 
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(b) Microfilariae (Ml) 
Cephalic space is more than W. bancrofti, the nuclei are round, irregularly 
spaced, overlapping and look blurred in stained preparations. The tail end 
contains two nuclei; this feature is unique in this species. Rests of the 
landmarks are same as that of W. bancrofti (Fig. 1.4). 
(c) Infective larvae 
The three caudal papillae are ill defined with bases and only slightly 
elevated. The central papilla is most prominent while two ventro-lateral 
papillae are less prominent. The anal ratio is 4. 
Major species of Brugia, which infect both man and animals are: 
(i) B. malayi (Lichtenstein, 1927): Human infection and is known to be 
widely endemic in South and East Asia. The sub-periodic strain has 
been fourd also in domestic and wild animals in Malaysia. 
(ii) B. pahangi (Buckley and Eseson, 1956): Occurs naturally in a wide 
range of animals in Malaya. It has been experimentally transmitted to 
a number of animal species, and also to man. 
(iii) B. patai (Buckley, Nelson and Heisch, 1958): Found in lymphatics of 
dogs, cats. 
(iv) B. buckleyi (Dijsanaike, and Panamonthan, 1962): Found in heart and 
blood vessels of the hare in Sri Lanka. 
(v) B. ceylonensis (Jayevvardene 1982): Found in lymphatics of dogs in 
Sri Lanka. 
2.2.7, Life cycle 
Life cycle completes in two host?, man is the definitive host where 
reproductive phase of the parasite occurs while mosquitoes are intermediate 
host provides environment for development of Mf into L3 (Fig. 1.2). 
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Fig. 1.2 Life cycle of Wuchereria bancrofti 
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Fig. 1.4 Brugia malayi microfilaria 
Fig. 1.5 Brugia malayi Adult worms in tissues of Mastomys coucha 
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2.2.2.1 Development in Mosquitoes 
Mf, which are circulated into the blood taken up by mosquitoes during their 
blood meal at night. In the mosquitoes, Mf (Li) shed their sheath and 
penetrates the stomach wall and migrates to the thoracic muscles where they 
settle down and further development takes place through two moults. The 
slender active Mf transforms into the short thick inactive sausage stage 
larvae, which has a slender tail (characteristic feature). After first moult the 
Li become short tailed L2 larva with 1 or 2 papillae at the caudal end. 
Followed by second moult the L2 grows to infective (L3) stage larva which 
measures between 1500 - 2000|im in length and 23 - 28|im in breadth with 
characteristic 3 ill defined caudal papillae. Infective larvae migrate to the 
abdomen and then to head and proboscis. At this stage L3 escape when 
mosquitoes take blood meal. 
2.2.2.2 Development in definitive host 
Infective larvae are introduced by the mosquitoes during their blood feeding 
on definitive host. These larvae are actively migrate through the wound and 
reach to the nearest lymphatics and settle down. Where they moult twice and 
develop into L4 and L5 stages followed by young adult stage and finally 
mature into male and female. After fertilization the female worms (which 
are ovoviviparous) give out young ones called Mf, which pass through 
lymphatic duct to various systems, pulmonary capillaries and to the 
peripheral circulation. The mean pre-patent period i.e. entry of L3 to the 
appearance of Mf in the peripheral blood is estimated to be about 9 - 1 2 
months in case of W. bancrofti and 3 - 4 months in case of 5. malayi. 
2.2.3 Periodicity 
W. bancrofti and B. malayi Mf show both nocturnal and diurnal periodicity 
during 24 hrs cycles. They live in the pulmonary capillaries and from there^ 
a proportion of the Mf population escape into the peripheral blood during 
night or day depending upon the species of Mf. In India, noctumally 
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periodic strain of bancroftian and baigian Mf are found. The noctumally 
periodic type shows a peak of Mf density in the peripheral blood between 12 
night and 2:00 am. Noctumally sub-periodic and diumally sub-periodic 
strains of Mf circulate throughout the 24 hrs with low density but their 
density increases during night or day, respectively. 
2.3 Lymphatic filariasis: Clinical manifestations 
2.3.1 Pathology and symptomatology due to Wuchereria bancrofti 
Following infection with L3 there is usually a period of vigorous immune 
responses to the invading larvae. If the larvae are not cleared from the body 
during this period then various pathologies associated with filarial infection 
can develop. Most of these conditions do not appear to arise from the effects 
of the nematodes themselves but from immune response to their presence. 
The most pronounced of these is the damage to the lymphatic vessels, which 
is mediated by the immune responses to the adult worms living in them. 
These immune responses are characterized by inflammation (Lymphangitis) 
of the affected area, generalized malaise and fever. Repeated episodes of 
lymphangitis or acute manifestations lead to the formation of fibrous and 
calcified tissues in and around the lymphatic vessels. These then results in 
chronic manifestations characterized by grotesque deformities and are 
usually unilateral. The sequential development of filariasis bancrofti may be 
classified into the following stages. 
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(i) The Biological incubation period 
The period from the time of entry of infection to the development of adult 
worms and appearance of Mf in the circulating blood. It has been estimated 
to require a year or more. For the B. malayi it takes 3 - 4 months. 
(ii) The patent but symptom less period (Secondary or carrier stage) 
This stage is characterized by the presence of Mf in the peripheral blood but 
without any clinical manifestations of filariasis. A considerable proportion 
of population remain microfilaraemic and asymptomatic for years together 
and in some instances for whole life. However some individuals become 
amicrofilaraemic while other may progress more rapidly to the acute and 
chronic stages. Recent studies have shown that most of the asymptomatic 
cases have lymphatic abnormalities as detected by lymphoscintigraphy and 
also renal abnormalities, which is evidenced by hematuria and/or proteinuria 
(Freedman et al, 1999. Dryer et al., 1992). 
(Hi) The acute or allergic stage 
The acute clinical manifestations of filariasis are characterized by episodic 
attacks of adinolymphangitis (ADL) with constitutional symptoms like 
fever, chills, malaise, nausea, headache and vomiting (WHO, 1998). In 
bancroftian filariasis the ADL attacks occur usually in the limbs, groin and 
the male genitalia are the most often affected during the acute stage, leading 
to funiculitis, epididymitis or orchitis. The repeated attacks of ADL precede 
the development of chronic lymphatic pathology of filariasis and these often 
continue for many years (Pani et al., 1994). ADL lasts for 3 - 5 days but 
some times for 15 days. Lymphoedema is frequently present during the 
episodes, but usually subsides after acute stage. Some times lymphoedema 
does not subside and lead to chronic changes (Dissanayaka et al., 1984). 
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(iv) Chronic manifestations 
The most conspicuous feature of clinical symptoms caused as a result of W. 
bancrofti infection is noted in the chronic stage. This occurs due to blockage 
of lymphatics. The major chronic signs are hydrocele, chyluria, 
lymphoedema and elephantiasis, which may differ in occurrence from one 
area to another. More serious are the blockage of the abdominal or thoracic 
lymph vessels, which eventually cause chyluria or hematochyluria. This 
stage is often incurable. 
2.3.2 Pathology and symptomatology due to B. malayi 
Symptoms due B. malayi infection are largely same as that due to W. 
bancrofti. However fever associated with lymphangitis in patients from 
endemic areas of B. malayi is more common than in those of W. bancrofti. 
Lymphoedema and elephantiasis of legs and arms are common in both but 
the absence of involvement of the genito-urinary organs is a characteristic 
feature of B. malayi filariasis. Though mostly limbs are affected, the upper 
extremities are much less frequently affected than the legs. 
2.3.3 Occult filariasis 
In occult filariasis the classical clinical manifestations are not present and 
Mf are not found in the blood, although they may present in the internal 
organs or tissues. Occult iilariasis is believed to result from a 
hypersensitivity reaction to filarial antigens derived from Mf This is 
considered as tropical pulmonary eosinophilia (TPE). TPE syndrome is 
characterized by nocturnal paroxysms of asthmatic symptoms, persistent 
eosinophilia and later by chronic interstitial lung disease (Piessens et al., 
1982). Occult filariasis with adult W. bancrofti in the anterior chamber of the 
eye has been reported by Arora & Das 1990). Other manifestation such as 
mono/polyarthritis, hematuria, glomerulopathies, endomyocardial fibrosis 
are also now well recognized. 
16 
Review of literature 
2.3.4 Endemic normals [Asymptomatic, amicrofilaraemic (EN)] 
In most of the endemic areas a proportion of the population remained Mf 
negative and is devoid of symptoms of the disease despite life long exposure 
to infection. It is possibly heterogeneous group consisting of "Truly 
Immune" cases apart from those with prepatent or sub clinical or unisexual 
infections of parasite. 
2.3.5 Opportunistic infections 
Lymphatic filariasis results in lymphatic impairment permitting 
opportunistic infections like bacterial and fungal. These secondary infections 
can lead, in turn, to more extensive pathology (WHO 1998). It is considered 
that these microbial fauna transmitted from infected mosquitoes. Among the 
bacterial strains with highest prevalence in tissue fluid, lymph and lymph 
nodes were Streptococcus, more over Micrococcus sp were also reported. 
Recently bacterial products of Staphylococci known as super antigens have 
been shown to be responsible for recurrent skin inflammation. Recently 
Olszewski et al, (1990) have shown that all these situations aggravate the 
filarial manifestations the super antigen activates and causes cytokine 
release and mast cell degranulation. 
2.4 Host-parasite interactions 
Due to long association immune response of host to parasite in filariasis is 
bound to develop. The immune mediated reactions result a wide range of 
clinical and pathological manifestations represented by asymptomatic 
carriers of Mf, symptomatic cases of filariasis with or without circulating Mf 
and extreme cases of elephantiasis. 
2.4.1 Defense strategies of the parasites 
Filarial worms develop defense strategies to survive in the host. They do not 
replicate in the human host. Thus for long-term persistence they have 
sophisticated mechanisms of immune evasion and modulation. The nature of 
these evasive mechanisms and the difference between protective and 
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pathogenic immune responses are the central questions and now being 
addressed in filariasis. Recent advances in the field of immunology and 
parasitology have highlighted a range of mechanisms by which the parasite 
actively modulates the immune response to allow its survival and induce 
chronic infections that persists over long periods of time in the host. 
2.4.2 Immuno-evasion 
This is an escape mechanism in which the parasites are surrounded by a non 
immunogenic host protein coat, to disguise it self as host component and 
then mask its crucial antigens so that it can fail to stimulate hosts immune 
response. 
An investigation carried out by Bright and Raj (1994) on the surface 
antigens of Setaria digitata by in situ localization revealed the occurrence of 
shared antigens in the egg, embryo, Mf and adult stages. It has been proved 
that the egg and embryo have exposed surface epitopes whereas the Mf and 
adults did not have such epitopes. The surface epitope hiding" is an 
immunoevasive strategy of the filarial parasite which explains why the 
naturally shed surface antigens evoke antifilarial immune response in the 
host even though the systems could not recognize the Mf or adult parasite 
due to lack of exposed surface epitopes. Antigen processing generally 
requires cestinyl and aspartyl proteases such as cathepsin B & D (Diment et 
al, 1990). Filarial worms release a cystatin like molecule, which may block 
cathepsin B. Interference with antigen presentation may not block the 
response, but also induce a state of immunological unresponsiveness, or 
tolerance. A key aspect of parasite persistence appears to be down regulation 
of the immune system resulting in tolerance or anergy. Moreover the 
production of protease is considered important for the conversion of the host 
tissues to nutrients and also for invasion and dissemination through host 
tissues to establish a suitable environment for the parasite to survive. 
Parasite can directly or indirectly blocks the effects of antibody with surface 
or released protease capable of degrading host Ig molecules (Auriault et al.. 
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1981). Filarial parasites use endogenous and exogenous arachidonic acid to 
produce and release prostanoids (Prostracyclin and PGE2), which in addition 
to the anti-inflammatory property may also inhibit T-cell proliferation (Liu 
et ai, 1990). Helminthes expresses surface secreted anti-oxidant enzymes 
such as super oxide dismutase (Simurda et al., 1988), glutathione peroxidase 
(GPX) (Cookson et al. 1992; Williams et al., 1992) and glutathione S-
transferase (GST) (Smith et al., 1986), counteract the oxidative burst of 
activated host leucocytes. Hence, helminth parasites have been shown 
specific molecular strategies to combat the threat of immediate immune 
attack by the host. 
Due to elaborate life cycle of the parasite, complex set of interactions with 
the host immune systems occur. Among the most important issues relating to 
parasite-host interaction is our clear understanding on defined parasite 
molecules in such interconnections. Particularly, relevant molecules in this 
regard are the molecules of ES products of the parasites. A variety of ES 
molecules from parasites have been implicated in the immune evasion 
strategies such as suppression in T ant B cell proliferation, alteration of 
macrophages and granulocyte functions, shedding of surface bound 
antibodies or ligand and modulation of the host inflammatory responses. 
Evidences suggest that ES antigens may also induce immunopathology and 
protective immunity. However there is a great realization about possible 
geographical variations in the prevalence and severity of different forms of 
the disease or genetic variation among the parasite species. Also there is a 
possibility of genetic variation in the endosymbiotic bacteria Wolbachia in 
exhibiting such variation. Hence there is a need for study of the molecular 
biology of all virulence attributes and their genetic diversity in order to 
develop suitable prophylactic measures. 
2.4.3 Humoral immune responses 
Increased immunoglobulin (Ig) response is well recognized in filarial 
infection. IgG is predominant Ig present in serum IgG subclasses differ in 
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number and location of disulfide bonds and the size of the hinge regions. In 
general, amino acid sequences of the four subclasses are over 95% identical. 
Except IgG4 all the sub classes can fix compliment. IgGi, IgG2 and IgG4 
subclasses can bind to staphylococcal protein A, but IgGs does not bind, 
IgGi is the major isotypes antibody among the IgG subclasses. In human 
IgG antibody responses to polysaccharides are mainly of IgG2 subclasses 
whereas protein antigens usually induce more prominent IgGi and IgGa 
antibody responses. In onchocerciasis IgGs has been associated with 
'Sowda' a chronic hyper-reactive oncho-dermatitis (Cabrera et al., 1988). 
The isotype analysis of IgG antibody subclass IgGi, IgG2 and IgGs isotypes 
were found to be present in very low concentration in microfilaraemic cases, 
but far more prominent in chronic cases (Hitch et al., 1991., Ottesen et al, 
1992; Kumiawan et al., 1993; Estamble et al., 1994 b; Maizels et al, 1985). 
Nevertheless, Hussain et al., (1987) observed high levels of IgGi in chronic 
patients but no difference could be detected in the IgG2 and IgGs levels 
between the microfilaraemic and symptomatic patients. IgGs antibody 
subclass response in patients with filariasis are supposed to be a predictor of 
individuals "at risk" for developing lymphatic or dermal pathology (possibly 
mediated by type III - immune complex mediated hyper-sensitivity 
reactions) (Ottesen et al., 1980; Cabrera et al., 1988; Boyer et al, 1991; 
Tsang et al., 1991; Hussain et al., 1992). IgGs subclass has been reported to 
play some role in protection (Boyer et al., 1991) also there are known 
biological functions for IgG2 apart from weak complement fixing activity 
and some binding to monocyte membranes (May et al, 1972). IgG4 subclass 
is usually predominant among specific antifilarial antibodies (Ottesen et al., 
1985) representing 50 - 95% of the total IgG response (Wong and Guest, 
1969; Finkelman et al., 1991; Kumiawan et al., 1993) in contrast to normal 
serum proportion of 2 - 5% (Aalberse et al., 1983). The patients with 
filariasis usually generate vigorous IgG4 antibody responses to their 
infections (Ottesen et al., 1985; Hussain et al., 1992; Kumiawan et al., 1993; 
Chanteau et al., 1991; 1992; Haabrink et al., 1995; King et al., 1995; 
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Maizels et al, 1995), whereas the normal humans appear generally 
incapable of mounting IgG4 responses to PC epitopes (Scott et al, 1987) 
suggested that specific lgG4 may be used as a diagnostic marker (Lai et al, 
1988; Chanteau et a/., 1991; 1994; Turner et al, 1992). In contrast to other 
subclasses high level of IgG4 subclass was found in TPE cases (Ottesen et 
al, 1985; Murthy et al, 1985) and in asymptomatic microfilaraemic 
individuals of lymphatic filariasis (Ottesen et al, 1985; Hussain et al, 1986; 
1987; Lai et al, 1988; Hitch et al, 1991; Ottesen, et al, 1992; Kumiawan et 
al, 1993; Estamble et al, 1994; Maizels et al, 1995; Murthy et al, 1995), 
Onchocerciasis (Cabrera and Parkhouse et al, 1986) and loasis (Egwang et 
al, 1989). The patients of lymphatic pathology (i.e. relatively hyper-
responsive individuals) have minimal or no IgG4 responses to parasite 
antigens (Ottesen et al, 1992). Interestingly IgG4 antibody was also found 
less in putative immune group (Stewart et al, 1995). The IgG4 levels in 
microfilaraemic patients correlated significantly with microfilarial density 
(Marleyefa/., 1995). 
It seems likely that antibody and humoral mechanisms initiated by these 
isotypes may contribute to the pathology through antibody dependent cell 
mediated cytotoxicity (ADCC) and immune complex formation. For 
example, IgGs is a major mediator of type III hj^jersensitivity, and is the 
isotype for which the human Fc-receptors on monocytes, macrophages and 
granulocytes have the highest affinity. It has also been observed that the 
antibody response was significantly associated with the development of 
latency or amicrofilaraemic pathological state of filariasis (Karam and Weiss 
et al, 1985; Fletcher et al, 1986; Boyer et al, 1991; Ottensen, 1992; 
Kumiawan et al, 1993). Some studies suggested that no correlation was 
found between the clinical manifestations and antibody responses (Estamble 
et al, 1994; 1995). A major feature of filariasis as with most other 
helminthic infection was a marked age dependency in prevalence of 
infection and disease i.e. changes in various antibody isotypes along with 
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age profile has been reported. (Hitch et al, 1991; Bundy et al, 1991; 
Meyrowitsch et al, 1995; Estamble et al, 1995). 
The increased level of various Igs has been reported by various workers in 
the sera of filarial patients (Towbin et al., 1979; Ottesen et al., 1982; 
Hussain et al., 1986, 1987, Sangvaranand and Zahner et al., 1989; Ottesen et 
al, 1992), as well as in experimental filarial infections (Subrahmanyam and 
Bagai, 1970; Ottesen et al., 1992; Baldwin et al., 1993; Ottesen and 
Ramchandran, 1995). As filariasis captures many essential characteristics of 
helminthic infection, the immune response to filaria parasites show a 
remarkable skewing of the humoral immune response towards IgE and IgG4 
and to some extent IgM and IgA as well (Hussain et al, 1981; Ottesen et al., 
1985). Investigations showed that the serum level of IgA is higher in 
chronic patients as compared to microfilaraemic patients (Ottesen et al., 
1982, Chanteau et al., 1992). The elevated levels of serum IgA in filarial 
subjects thought to have pathogenetic significance. IgA antibodies have been 
little examined in filariasis but perhaps they deserve closer attention. IgM 
responses in filarial cases are still not clear, previously it was thought that 
IgM antibodies are related to Mf clearance (Weiss and Tanner 1979; 
Thompson et al., 1981, Lawrence and Denham, 1992). Amicrofilaraemic 
filarial cases have been shown to have significantly greater IgM antibody 
response to adult parasite antigens than the patients with microfilaraemia 
(Piessens et al, 1980a; Ottesen et al, 1982). On the contrary other studies 
revealed the higher level of IgM antibodies in acute filarial cases while 
lower concentrations were reported in other forms of clinical manifestations, 
endemic normals and non endemic normals (Ata et al., 1993) presumably 
because of their reactivity to PC and other non-protein determiiiants 
(Gutman and Mitchell, 1977, Almond and Parkhouse, 1986; Gualzata et al., 
1986; Lai et al., 187; Maizels et al., 1987) or reflecting the cross-reactivity 
of IgM with other nematodes. The PC antibody responses recently have been 
shown to be subclass restricted in humans (Scott et al., 1987). PC epitope 
containing antigens are located mainly within the reproductive organs and 
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eggs of female worms (Mak et al., 1993), so quantification of serum levels 
of PC epitope can be used to quantitate the female adult worm load (Wenger 
et al, 1988). Heat stable filarial PC bearing circulating filarial antigens have 
also been defined (Forsyth et al., 1985; Maizels et al, 1987). 
2.4.4 Cellular immune responses 
Evidence of involvement of cellular immunity in filariasis was first reported 
by Bagai and Subrahmanyam (1970), who observed the death and 
disintegration of Mf by various cells in the pleural cavity of rats infected 
with rodent filariid, Litosomoides carinii which develop latency after a 
period of patent microfilaraemia. Later on several other workers (Higashi 
and Chowdhury, 1970; Weiss and Tanner, 1979; Sim et al, 1982; Aggarwal 
et al, 1985; Haque and Capron et al, 1986) also demonstrated the antibody 
mediated cellular adherence and destruction of Mf and L3 of various filarial 
species. 
Delayed type hypersensitivity reactions have been assessed in vitro in 
response to filarial antigens (Ramachandran et al, 1974; Ottesen et al, 
1977; Piessens et al, 1980; Nutman et al, 1987a; Leiva and Lammie, 1989; 
Hitch et al, 1991; Soboslay et al, 1991; King et al, 1992). Most of the 
cellular immune studies have been carried out using crude filarial antigens. 
Understanding the immune response at molecular levels is important for the 
development of strategies to cure and control of the disease. Certain 
fractions were identified as stimulatory (Lai et al, 1987), few as suppressive 
(Wadee et al, 1987) and some as mitogenic (Piessens and Wadee, 1986). 
lAA.XThl and Th2 type cytokines 
Upon antigen stimulation, CD4+ T-helper (Th) cells differentiate into two 
distinct subpopulations, the T-helper 1 (Thl) or T-helper 2 (Th2), each 
producing unique cytokines and mediating separate effector function 
(Mossman & Coffman, 1989). Thl cells produce IL-2, TNF-a and IFN-y 
activates macrophages and induces delayed type hypersensitivity responses 
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and cell-mediated immunity. By contrast, Th2 cells produce IL-4, IL-5, IL-
10 and IL-13, which are responsible for stimulating production of mast cells, 
eosinophils, and IgGi and IgE antibodies and are involved in promoting 
strong humoral immunity possibly suppressing the cellular immune response 
including inhibition of several macrophage functions. Each subpopulation 
regulates the other through their different cytokine profiles. Thl and Th2 
cells not only produce different sets of cytokines, which results in distinct 
functional properties, but also exhibit the preferential expression of 
activation of some molecules. Thl cells are suitable for protection against 
intracellular parasites whereas extra cellular parasites are best counteracted 
by a combination of Th2 and Thl type cytokines. The optimal reaction 
against metazoan parasites is provided by Th2 cells, which also inhibit 
development of Thl and macrophages, which may be harmful to the host. 
Thl and Th2 dominated responses not only provide different modalities of 
protection against exogenous offending agents but may also play a critical 
role in the development and or maintenance of the other pathophysiological 
conditions. However, by and large the mechanism underlying that induction 
of polarized subsets is not clearly understood. 
2AA.lFilarialparasite and Thl/Th2 cytokines 
An adult worm in the lymphatics causes early lymphatic dysfunction and 
dilatations etc. due to factors released by the parasites or the host parasite 
interaction. In the early lymphatic dysfunction production of down-
regulatory molecules are thought to occur. These molecules inhibit 
inhibitory responses. This hypothesis is supported by the recent findings that 
the cytokine responses in microfilaraemics are of Th2 type i.e. heightened 
production of IL-4, IL-5 and IL-10 that are anti-inflammatory (King et al, 
1993; Maizels et al., 1993) in nature. Th2 cytokines in asymptomatic 
microfilaraemics facilitate persistence of the parasite in the host while 
inducing little or no inflammatory clinical disease. IL-4 stimulates B-ceJI 
proliferation resulting in IgG4 and IgE production, where as IgG4 as 
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blocking antibody with consequent reduction of the inflammatory activity of 
IgE (Maizels and Lawrence, 1991). Impaired lymphocyte proliferative 
responses to filarial antigens and characteristics Th2 cytokine production in 
microfilaraemics have also been reported by Ravichandran et al, (1997) and 
Mahanty and Nutman (1995). This depressed T-cell response, specific to 
filarial antigens, is regarded as a form of tolerance and in contrast to the 
responsiveness among both endemic normals and chronic symptomatic 
cases. It has been established that a profound state of hypo-responsiveness or 
immunological tolerance exists towards adult and Mf antigens in the large 
group of Mf carriers who are asymptomatics. However tolerance in general 
does not shut down all immune responses. For example, IgE and IgG4 
antibody responses can be extremely strong and infection is accompanied by 
high levels of circulating eosinophils (Wong Guest et al, 1969). These facts 
are known to promote by the Tc cells, which exist in a reciprocally 
inhibitory network with a separate population of Thl cells. In filariasis there 
is partial tolerance among Thl subset rather than a broad ablation of cell 
pathways of responsiveness. Mahanty et al, (1996) reported that 
proliferative response to male worm antigen was same in both Mf and 
pathological cases. Moreover the antigen driven cytokine secretion by 
PBMC revealed significantly lower IL-2 and IFN-y production in Mf 
carriers with male antigen. This observation proved that Mf carriers exhibit 
preferentially impaired Thl type responses to Mf antigen and that Mf 
induced IL-10 may be critical in the down-regulation of specific Thl 
responses. This was supported by investigations carried out by various 
workers (Urban et al, 1991, 1992) that IL-10 is involved in the down 
regulation of antigen responsiveness in parasitic infection. This inhibitory 
mechanism may occur either through the ability of IL-10 to inhibit 
expression of MHC Class II molecules on APC (de Waal Malefyt et al, 
1991) or by inhibiting the expression of certain co-stimulatory molecules. 
However when anti-IL-10 antibodies were added into the lymphocyte 
culture (Pearlman et al, 1993), T cell proliferation and Thl cytokine 
25 
Review of literature 
production enhanced. Conversely, in a study of Haitian population, levels of 
IL-10 produced in response to filarial antigen of B. pahangi were highest in 
PBMC from patients with lymphatic dysfunction and lowest in 
microfilaraemic persons. Neutralizing antibodies to IL-10 failed to restore 
the in vitro proliferative responses to filarial antigen in microfilaraemic 
individuals. Recently Steel and Nutman (1998) have demonstrated that 
CD45 RA^CD4^ cells from normal individuals when incubated with Mf 
soluble antigen in presence of APC in vitro, Mf antigen induced 
proliferation and IFN-y and IL-5 production. This suggested that filarial 
antigens can prime the CD45 RA^ CD4"^  cells in vitro and can deviate the 
immune responses either to typel or type2 cytokine production. 
Activation of human T cells induces changes in many cell surface-associated 
molecules. In brugian filariasis, the lower frequency of CD8+ cells has been 
observed in microfilaralemic compared to non-endemic controls (Piessen et 
al., 1982). Over and above several factors have been reported to play a role 
in the induction of Th subsets including the properties of antigen, dose of 
antigen, site of exposure and ongoing immune response in the host. For 
instance, it has been suggested that proteases, required by multicellular 
organisms for tissue penetration induce Th2 response against multicellular 
parasites (Urban et al., 1992). In primary culture, increasing dose of antigen 
has been reported to switch the immune response from Thl to Th2 or vice 
versa; decrease in antigen load can result in progress from Th2 to Thl 
(Hosken et al., 1995). Moreover, it is suggested that fully differentiated Thl 
cells are stimulated by moderate but not high doses of antigen, whereas Th2 
cells respond over a wider range of concentrations. Although initially it was 
thought that different APC types would selectively influence T cell 
differentiation, it is now known that dendritic cells, macrophages and B cells 
are all capable of inducing differentiation of Thl or Th2 cells in the presence 
of the appropriate cytokines (Ronchese et al., 1994). Mouse studies show 
that the presence of IL-4 during the initial priming of naive T cells by 
antigen results in the generation of Th2 cells that produce IL-4 and IL-5 both 
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in vitro and in vivo, whereas the differentiation of IFN-y producing Thl cells 
is inhibited (Hsich et al., 1992, Seder et al., 1992, Croft et ai, 1992, 
Romagnani et al, 1992). Thus, IL-4 is critical in Th2 development. 
However, recent studies indicate that an IL-4 independent, IL-1 mediated, 
pathway of Th2 cell proliferation does exist (Huber et al., 1996). In contrast, 
IL-12, which produced by macrophages, dendritic cells and B cells is the 
dominant factor in inducing the differentiation of naive CD4+ cells to IFN-y 
producing antigen-specific Thl cells (Hsich et al., 1993, Seder et al., 1993, 
Manetti et al, 1993). In contrast to these events in microfilaraemic cases, in 
amicrofilaraemic patients with chronic lymphatic pathology, there is break 
down of tolerance to parasite leading to development of relatively pro-
inflammatory Thl response. This is associated with a high level of IgE, IgGi 
and IgG2 and low levels of IgG4. Elephantiasis may result by IgE mediated 
mechanisms or a passive reaction to naturally dying adult worm evolving 
IgG, and IgG2 antibody response mediated inflammatory reactions. This 
immunological hyper-responsiveness may remove parasite from circulation 
and develops lymphoedema (Olszewski et al, 1997). 
Studies in animal model showed that adult worms or Mf when implanted 
into mice would survive for a limited period of time and stimulate 
contrasting Th cell subsets, i.p. inoculation of Mf initially induces a strong 
Thl cell response with the induction of IFN-y. This IFN-y response 
continues during infection, although lL-4 and IL-5 responses develop later. 
The Ig isotype profile reflects the strong IFN-y influence with marked IgG2a, 
IgG2b and IgGs responses in addition to IgGi (Lawrence et al, 1994). 
Similarly, a single s.c. immunization with soluble Mf antigen also induced 
IFN-y whereas repeated immunization stimulated lymph node cells and 
spleen cells to produce both IFN-y and IL-5. Peritoneal exudates cells from 
multiple immunized animals that were subsequently chaJienged i.p. with Mf 
produced only Th2 cell responses (Pearlman et al, 1993). These studies 
suggest that chronic exposure to Mf may lead to the development of Th2 
cells but a critical threshold must first be reached. Nevertheless the route of 
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infection has been suggested to have a strong impact on the type of immune 
response ehcited, as Mf inoculated intravenously induce high level of IgE in 
addition to IgG2a, IgG2b, IgGs and IgGi (Lawrence et al., 1994), whereas IgE 
is absent when Mf are injected i.p. (Pearlman et al., 1993). In contrast to Mf, 
adult worms, particularly female worms and L3 stimulate Th2 cell responses 
with high IL-4, IgGi an IgE production (Lawrence et al., 1994). ES product 
is thought to be responsible for this skewing of the immune response to Th2 
direction. Moreover, in IL-4 deficient mice, adult worms particularly female 
worms induce Thl responses characterized by high levels of IgG2a, IgG2b, 
IgGs and IFN-y (Lawrence et al., 1993). This indicates that the induction of 
Th2 cell responses by adult female worms is entirely dependent on 
stimulation of IL-4. 
2.4.5 Immunomodulation 
This is seen as an active interaction with the host's defense system to reduce 
the impact of the response against the parasite. The parasite factors can do 
dual function, (i) Suppressive activity of the parasite factor leads to down 
regulation of the host's defense system and (ii) Stimulating factor 
responsible for stimulating cell populations. This situation leads to 
disturbances in balancing of the type I - type II response, which thereby 
causes general suppression of the B and T cell responses and mimicry of the 
host proteins that direct the immune response (Riffkin et al., 1996). 
The mechanisms underlying this parasite - specific anergy may involve 
adherent suppressor cells, serum suppressive factors or suppressor T 
lymphocytes (Piessens et al, 1980). The suppressor cells may be induced in 
vitro using filarial antigens and patients with patent Mf had either a large 
number of suppressor cells or the hyper functional activity of these cells. On 
the other hand the anergic state may result from a diminished number of 
parasites antigen responsive lymphocytes (Nutman et al., 1987) as a 
consequence of prenatal sensitization or tolerance to the parasite (Stee/ ^ 
al, 1994). Removal of suppressor cells restored the lymphocyte reactivity 
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(Piessens et al., 1982). Similarly lymphocytes from microfilaraemic 
individuals who are hypo-reactive to filarial antigens exhibited increased 
proliferative ability after the same subjects were treated with DEC (Suba et 
ai, 1997). The immunosuppressive effect of 5. malayi adult worm extract 
on PHA driven T cell proliferation were studied in filarial patients by Lai et 
al, (1990). They have demonstrated that the suppressive agents appeared to 
be the PC containing agents that were present in abundance in the parasites 
and in circulating filarial antigens. King et al, (1992) have observed the 
diminished parasite specific T and B cells in microfilaraemic individuals by 
measuring the proliferative responses of T and B precursors (CD3+) to the 
parasite-specific antigens and a mitogen. The frequency of parasite-specific 
CD3+ T cells was significantly lower in Mf carriers than in chronic patients. 
However the frequency of mitogen or non-parasite specific CD3+ T cells 
were same in chronic patients and microfilaraemic individuals. 
2.4.5.1 Immune suppression 
The immunological tolerance, that plays an important role in modulating the 
dynamics of infection and disease (Nutman et al, 1987b; Lammie et al, 
1991; Maizels and Lawrence, 1991) based on two concepts. Appropriate 
parasite antigens that may induce an anergic state in the host increasing the 
duration of infection and possibly reducing the subsequent 
immunopathology. Several workers suggest that distinct immunological 
defects exist in patients with asymptomatic forms of patients where adults 
and Mf survive within the host for prolonged period by avoidmg the host 
immune responses, maximizing the chances of infection transmission. Direct 
immunosuppression of T cell responses by parasite antigen was evidenced 
by prolonged hypo-responsiveness in microfilaraemic individuals (Ottesen, 
et al, 1992). Though molecules shed from the parasite can directly suppress 
lymphocytes of asymptomatic Mf positive infected individuals (Wadee et 
al, 1987; Lai et al, 1990), yet the mechanism underlying the immunological 
hypo-reactivity remains poorly defined. A number of possibilities have been 
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proposed, including the development of immune tolerance (Nutman et ai, 
1987), active suppression by monocytes (Piessens et al, 1980), suppresser T 
cells (Piessens et al, 1982) or soluble suppressive parasite products 
(Piessens e/a/., 1980). 
Anergy may be established to only one part of the parasite life cycle. Thus 
microfilariamia with bancroftian filariasis are found with high titres of 
antibody to the surface of L3 although such individuals are universally 
devoid of antimicrofilarial surface antibodies. The ability to mount strong 
responses to the L3 larvae in the face of adult and Mf-directed tolerance may 
be an essential aspect of filarial immunity. In animal models responses to 
antigen from adult and microfilarial stages may also be regulated at 
independent levels in cats and rodents' models, same animal may kill adult 
worms but retain circulating Mf, while other clear Mf. But are unable to kill 
the adults. Responses causing pathology are stage specific filarial infection 
therefore energies host responses to adult and microfilarial antigens. In 
lymphatic filarial infection once individuals re-express their antifilarial 
responses, they may be able to kill resident adults and Mf and thereby 
eliminate immunopathogenesis. However such people will continue to be 
exposed to new L3 from mosquito vectors. If incoming L3 are able to mature 
through L4 stage in the non-tolerant host, they may act as renewed target for 
aggressive reactions generating acute clinical manifestation, lymphatic 
lesions and over time the calculative damage of chronic disease. Thus it 
seems clear that post L3 stages are responsible for lymphatic pathology. 
In contrast to the concept of active suppression it has been proposed that 
some individuals develop immune tolerance to filarial infections either from 
prenatal or prenatal sensitization to parasite antigens. This hypothesis is 
supported by the recent observation that microfilareiamic individuals with 
W. broncrofti have marked diminished parasite responsive T and B cells 
compared with amicrofilariamic individual. Finally there is probably a 
genetic regulation of the host response to parasite antigen that may account 
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for differential susceptibilities and clinical manifestations of the disease 
observed among individuals. 
Suppression of spleen lymphocyte responsiveness in jirds with a chronic B. 
pahangi infection does not correlate with reduced humoral or cellular 
responsiveness to heterologous antigens in vivo. Evidence that splenic 
suppressor cells does not interfere with the in vivo capacity of chronically 
infected animals to develop immune responsiveness to heterologous antigen 
suggest that these cells may represent a population undergoing commitment 
to an antigen specific regulatory activity. This interpretation is supported by 
the absence of both in vitro mitogen and antigen specific reactivity of spleen 
cells from chronically infected jirds. 
2.4.5.2 Mechanism of hypo-responsiveness 
In endemic areas majority of individuals with Mf in circulation appear to 
remain clinically asymptomatic for years with only a minority progressing to 
the acute and chronic stages of infection in spite of the fact that the whole 
population is exposed to repeated bites of infective mosquitoes. Several 
studies both in human and experimental models have shown that immune 
response of such individuals are profoundly altered, most notably there is a 
diminution of parasite specific lymphocyte proliferation, IL-2 and IFN-y 
production, an increase in antifilarial IgG4 and the production of regulatory 
cytokines IL-10 and TGF-p. Many mechanisms pertaining to these 
diminished in various arms of the immune responses have been put 
forwarded. Among the various mechanisms proposed data generated from 
human patients suggest that they may be related to antigen concentration, 
antigen presentation, and most recently apoptosis and suppression. In 
apoptosis activation induced or programmed cell death leading to deletion of 
microfilarial exposed T cells mechanisms have been proposed to be one of 
the reasons responsible for lack of cellular proliferation in Mf carriers. 
Indeed cells that survive activation induced cell death produce high levels of 
IL-4 and IL-10 suppress the proliferation of other antigen-specific T cell, 
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suggesting a mechanism that could prolong in vivo tolerance. Apoptotic 
pathways have been looked at in human filarial infection. In vitro studies 
have shown that high dose of microfilarial antigen in presence of primed 
CD4+ CD45 RA cells, induces both loss of viability and increased annexin 
positivity on re-exposure to parasite antigen. In vitro condition fiirther 
proved that mice exposed to B. pahangi Mf resulted increased number of 
apoptotic cells. PBMC from Mf positive patients were found to express low 
levels of CD80 mRNA compared to uninfected individuals. Anti-CD28 
antibody failed to restore proliferation among anergic T cells. PBMC from 
Mf positive patients demonstrated diminished expression of CD80 on 
CD 14+ cells. However, these findings need clarification. IL-10 and TGF-P 
have emerged as regulators of T cells responses. Findings have been shown 
that there was an inverse relationship between IL-10 production and T-cell 
proliferation (Sartono et ai, 1995). However a detailed knowledge of the 
processes that modulate antigen specific responses is immensely required. 
High levels of Mf have been shown to lead to the down regulation of both 
Thl and Th2 induced antibodies or only Thl arms. A positive correlation 
was found between Mf load and IgG4 antibodies, however it was also found 
that Mf negative adult worm in carriers have similar kind of down regulation 
of host immune response suggesting other mechanism must also play a role 
in this. Filarial derived factors have also been isolated that interfere with T-
cell functions. Secretion of immunodominant molecules such as PC may act 
as an inhibitor of T-cell reactivity (Harnett et al., 1999;). Other molecules 
like cystein protease inhibitor, which account for much of the "suppressive 
activity of filarial ES product on T-cell proliferation in murine model 
studies. Nevertheless antigen specific unresponsiveness in filariasis can be 
clearly understood using the modem tool developed for genomics and 
proteomics. 
2.4.6 Parasite specific immune response to defined antigens 
One of the major obstacles to the study of parasite specific immune 
responses has been the lack of well-defined parasite antigens. Indeed most 
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investigations of the immune responses in filarial infections have relied on 
crude soluble antigen preparations to examine the relationship between the 
structure of the antigen and the immune response it engenders. Recent 
studies have begun to characterize biochemically purified and recombinant 
antigens that can stimulate different arms of immune system (Lai et al, 
1987). Preliminary studies of T-cell epitopes of recombinant B. malayi 
antigens may help to define the namre of antigenic signals necessary for the 
induction of the IgE and eosinophil responses. 
Analysis by immunoblotting revealed parallel specificities for IgG and IgE 
despite different patterns of antigen recognition among individual patients 
(Hussain et al, 1986). The results showed that for almost all antigens 
recognized by IgE. there was a coixesponding binding of IgG. When 
analyzed further this was found to be predominantly due to the IgG4 isotype 
(Ottessen et al, 1985, Hussain et al, 1986). Qualitatively, patients 
harbouring Mf possessed IgG4 antibody levels 2 - 2 0 times higher than 
patients with chronic lymphatic obstructive pathology (Hussain et al, 1987). 
Quantitative analysis with the same sera revealed major differences in the 
recognition profiles of IgG isotypes. The IgGl and IgGj responses in 
patients with elephantiasis were directed mainly towards antigens in the 
molecular weight range of greater than 68 kDa, whereas in microfilaraemics 
these responses were against antigens m.ainly less than 68 kDa (Hussain et al 
1987). Recently, the reciprocal relationship between specific IgE and IgG4 
antibody responses to total parasite extract (Kumiawan et al, 1993) and to a 
secreted antigen of filarial parasite, gp,'^ '^^ °° have been studied (Paxton et al, 
1993). Persons with active infection were found to have low levels of IgE 
and high IgG4, whereas chronic lymphatic disease often associated with low 
or no Mf showed higher IgE:IgG4 ratios (Kumiawan et al, 1993). IgE has 
been thought as a protective isotype against helminthes (Butterworth et al, 
1987), which is supported by data from work using a feline filariasis model 
showing a m.ajor role for IgE in elimination of the adult worms (Baldwin et 
al, 1983). Elevated levels of IgG2 and IgG^ have been associated with 
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chronic disease. These isotypes were substantially higher in elephantiasis 
patients compared to microfilaraemics (Kumiawan et al, 1993). These 
findings suggest that epitopes directed against these isotypes may be helpful 
in determining the nature of antigens that may reveal functional 
characteristic with respect to pathogenicity or prophylaxis. 
All nematodes are covered by a cuticle, which is a multilayered structure 
elaborated by an underlying hypodermis (Lee, 1966, Bird, 1971). The Mf of 
W. bancrofti, and Brugia species are enclosed in a sheath derived from the 
original egg shell and are distinct from those of onchocerca, mansonella 
who are devoid of sheath (Bain, 1975; Vincent et al, 1975). The antigenic 
determinants on the surface of Mf presumably play an important role in 
initiating immune evasion. The emphasis is justified by various studies on 
different filarial parasites, which demonstrated that the disappearance of Mf 
from the host circulation is correlated with the appearance of anti-surface 
antibodies to Mf (Hedge and Ridley, 1977; Wong and Suter, 1979). Several 
methods have now been used for extrinsically labeling the exposed 
molecules on surface of filaria parasites including Chloramine-T (Baschong 
and Rudin, 1982), Lactoperoxidase (Baschong and Rudin, 1982), Bolton-
Hunter reagent (Maizels et al, 1983a; b) and lodogen (Forsyth et al, 1981). 
These techniques permit the characterization of surface antigen molecules 
and assessment of immunological specificity of each molecule. Over the last 
few years a class of cuticular proteins and glycoproteins has been identified 
in many genera of parasitic nematodes including. D. immitis (Philipp et al, 
1986), A. viteae (Baschong et al, 1982), Onchocerca sp. (Lobos and Weiss, 
1987), B. malayi (Maizels et al, 1983b), B. pahangi (Maizels et al, 1983b; 
1985a; Sutanto et al, 1985). B. timori (Maizels et al, 1983 a; b) and W. 
bancrofti (Maizels et al, 1986). A number of reactive surface proteins of 
different life-stages oi Brugia sp. e.g. 12, 14 and 31 kDa, of L3, 33 and 70 
kDa (Selkirk et al, 1986) of Mf and 45, 70, 85, 100, 160 kDa (Sutanto et al, 
1985), 16 and 29 - 30 kDa (Maizels et al, 1985; Storey and Philipp, 1992) of 
adult filarial parasites have been analyzed earlier. A number of common 
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antigenic determinants between different life-stages of W. bancrofti, B. 
malayi (Maizels et al, 1983b), B. pahangi (Philipp et al, 1986), L. carinii 
(Philipp et al, 1984), and other nematodes (Philipp et al, 1981; Maizels et al, 
1982) have been characterized by radio iodination technique. Common 
antigenic molecules have also been demonstrated between different species 
of filarial parasites (Forsyth et al, 1981; Lai et al, 1987; Philipp et al, 1988). 
Changes in the surface molecules during differentiation and growth have 
been demonstrated for certain filarial parasites (Maizels et al, 1982; Philipp 
et al, 1980; 1988) including other helminths (Philipp and Rumjaneck, 1984), 
indicates that these molecules may not appear to be targets for a protective 
response. Apart from surface antigens, filarial nematodes release a variety of 
antigenic molecules in host in the form of ES products. Much attention has 
been focused on the involvement of ES products of various filarial parasites 
like S. cervi (Malhotra et al, 1987), L. carinii (Ishi 1970), B. pahangi 
(Maizels et al, 1985b) and B. malayi (Petralanda et al, 1986). Microfilarial 
and adult E/S products have also been characterized in different filarial 
parasites including A. viteae (Dikshit et al, 1994; 1995), B. malayi (Kaushal 
et al, 1982, Chenthamarakshan et al, 1996), W. bancrofti (Weil and Liftis, 
1987; Zheng et al, 1987; Reddy et al, 1989; Cheirmaraj et al, 1991). 
The somatic antigens have been fractionated earlier derived from a number 
of filarial parasites including W. bancrofti (Kaliraj et al, 1982; Maizels et al, 
1986; Weil and Liftis 1987); A. viteae (Wandji et al, 1990) and B. malayi 
(Selkirk et al, 1986; Maizels et al 1983b, 1986; Lai et al, 1988). A number 
of anfigenic molecules viz. 44, 40, 38, 31, 32, 22, 19, 18, 16 and 14 kDa of 
B. malayi (Cheirmaraj et al, 1991), 25 kDa (Kazura et al, 1986), 92, 88, 86, 
79, 73, 68, 66, 62, 58, 6, 54, 5, 43, 38 and 25 kDa (Parab et al, 1990) of Mf 
were earlier found to be immunoreactive using human bancroftian sera. 
Some molecules were found protective viz. <200, 170 - 200, 40 - 44, 30 -
36, 23 - 28, 20 - 22 and 17 - 19 kDa of B. malayi adult worms, which 
induced protection against L3 in balb/c mice (Hammerberg et al, 1989). 97 
kDa of B. malayi Mf and adults induced partial stage specific protection 
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against B. malayi Mf in mice (Nanduri and Kazura, 1989). It is apparent 
from the above review of literature that various attempts have though been 
made to characterize antigens of different filariid species, the information 
are patchy. In fact, not much concerted efforts have been made to purify the 
identified immunogenic molecules of human filariid and to evaluate their 
immunogenicity or diagnostic efficiency. It therefore, appears necessary to 
identify such molecules in the target human filarial species and to evaluate 
their potential in the host parasite interaction. 
2.4.7 Clinical diagnosis - Its limitations 
The clinical manifestations of filariasis are not consistent with all the 
patients. Many times the definite diagnosis takes the support of evidence like 
history of patients having lived in filaria endemic area and the presence of a 
Mf positive individual in the same home and demonstration of filarial 
antibodies etc. (WHO 1987). The diagnosis of occult filariasis is much more 
diflicuh in the absence of Mf or classical manifestations. A favorable 
response to DEC provides additional evidence. Supportive evidences like 
detection of parasite antigen or antibodies is very much helpful to establish 
association of these conditions with filariasis. 
2.4.8 Immunodiagnosis of filariasis - The present status 
Nevertheless before applying any new strategies and methods of control in 
large-scale campaigns, reliable, practical techniques are necessary to assess 
accurately and rapidly the distribution of infection, its level of endemicity, 
and amount of associated diseases. Further changes in these parameters for 
evaluation of outcome of the control measures are necessary to monitor and 
record. 
The major limitations in parasitological and clinical diagnosis of filariasis 
have necessitated the development of immunodiagnostic tests (Kagan, 1980; 
Harinath et al. 1984). One of the main hurdles in the development of suitable 
immunodiagnostic test for bancroftian filariasis is the paucity of parasite 
materials. There is no easily transmittable animal host for W. bancrofti. 
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Hence antigens from other human filarial parasite B. malayi closely related 
to W. bancrofti have also been explored. Further since filarial antigens are 
expressed at different stages of the life cycle of parasite, antigens from 
different stages of the filarial parasites have been employed. There are two 
main approaches in the immunodiagnosis of filariasis i.e. (i) Based on 
detection of antibodies and (ii) Based on detection of parasite antigen. Post-
genomic development of modem immunodiagnostic techniques using 
recombinant DN A technology has recently led to the development of rapid 
and high-throughput antibody and antigen based kits by various groups. A 
high degree of positive / negative response was observed for 3 tests and the 
sensitivity for detecting microfilaraemic cases was 100% for all tests. Some 
of them are in market (ICT, OG4C3 and DNA probes) and some are in 
pipeline. However these have some shortcomings in relation to specificity 
(parasite varies with geographical areas) and cross reactivity (immunological 
cross-reactivity among various nematodes) and should be taken care of for 
developing better techniques. It is not out of place to repeat that filarial 
parasites undergo complicated life cycle with various life stages, 
development of a suitable stage specific diagnostic methods becomes 
immensely needed. Studies on reinfection after therapy and resurgence of 
infection due to relapse or constant exposure of infection from mosquito 
bites using animal models are required to understand the spread of the 
disease / holistic filarial manifestations. 
2.5 Treatment 
Drugs are the main stay for controlling many diseases, but antifilarial drugs 
(Table 1.2) present a considerable challenge for researchers interested in 
rational drug development. Despite the existence of filarial parasites of man 
causing elephantiasis is known since mid 18* century, in fact routine 
chemotherapy of potential antifilarial compounds was started as late as in 
1944 by Culbertson and Rosewbrough against cotton rats naturally infected 
with L. carina. In 1947 Hewitt et al., discovered and introduced DEC a 
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piperazine derivative as antifilarial agent. Since the ill effects due to filarial 
parasites are not fatal as those caused by bacteria and viruses, relatively less 
attention, has been paid towards control of filariasis. Thus, it is not 
surprising that propoitionally the number of suitable antifilarial is very 
small. Success in the development of new drugs is largely dependent on 
reliable screening models, rational design of molecules, and usage of 
standard screening techniques. Of these the former plays a pivotal role and 
requires better understanding of the host-parasite relationship, as insufficient 
knowledge regarding parasite biology would lead to erratic and inconsistent 
results. The rudimentary knowledge on filarial models we had in the past 
was peihaps the main hurdle in the development of effective medicaments 
against filarial diseases. 
The qualities of a good antifilarial should be 
(i) It must reach the habitat of the parasite. 
(ii) The drug should not have harmful effects on the host tissue. 
(iii) It must attack the vital organs of the parasite. 
(iv) It must destroy the parasite or affect its expulsion without producing 
adverse/toxic effects in the host. 
(v) The organism should not develop resistance 
(\'i) It must be cheep and easy to administer and be effective in single 
dose, which may be beneficial for mass treatment. 
With the advent of test models developed from time to time, success has 
been achieveo and some effective and partially safe antifilarial have been 
developed (Fable 1.2). 
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2.6 Control of lymphatic filariasis 
Over the past 50 years, since the first introduction of DEC in 1947, several 
endemic countries/territories have expanded considerable effort to control or 
eliminate lymphatic filariasis. The control of LF can be achieved as follows: 
2.6.1 Vector control 
Among the vector control strategies the most promising are biocides, 
especially Bacillus sphaerieus (a self producing, toxin-producing 
bacterium), for the control of Culex quinquefasciatus mosquitoes (Hougard, 
et al, 1992), polystyrene beads to limit the breeding of vectors, especially in 
enclosed urban breeding sides, such as latrines and Cesspits. Insecticide 
impregnated bed nets and curtains; such as those used for malaria indoors 
spraying of insecticides that are long lasting and residually active. Over and 
above for the long-term successful application of all these methods of vector 
control, community participation is essential. 
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Table 1.2 Some effective antifllarials and their mode of action 
Chemical class 
Piperazine 
Cyanine 
Dyes 
Arsenicals 
Organo 
phosphate 
Imidazole 
Napthalene 
Salphonic acid 
Amosconate 
Antimonial 
Benzimidazole 
Avermectin 
Nitroflirans 
Agent 
Diethylcarbam 
azine 
Cyanine-863 
Arsenamide 
Metrifonate 
Levamisole 
Suramin 
Isothiocyanate 
Stibophen 
Albendazole 
Ivermectin 
Furazolidon 
Efficacy 
MIF 
(Hewitt et al, 
1947) 
MAP 
(Peters etal, 1949) 
MAP 
(Otto etal, 1952) 
MAP 
(James etal, 1974) 
MAF/MIF 
(Tulloch et al, 
1971) 
MAP 
(Duke etal, 1977) 
MIP/MAF 
(Sazetal, 1977) 
MAP 
(Katzetal, 1977) 
MAP 
(Mark etal, 1984) 
MIP 
Cambell et al., 
1983 
MAP 
(Lammler et al, 
1978) 
Mode of action 
Hyper-polarization of Muscle 
Membrane (Del Castillo et al, 
1964) 
Inihibition of Glucose Transport 
(Bueding et al, 1960) 
Binds to Sulphydryl proteins 
(Otto etal, 1952) 
Inhibition of Acetyl 
cholinesterase (Bueding et al, 
1972) 
Cholinergic agonist 
(Forbes et al, 1972) 
Inhiition of folate Metabolism 
(Jafeeetal, 1980) 
Inihibitory effect on 
Carbohydrate Metabolism 
(Nelson etal, 1984) 
Inhibition of Phospho 
fructokinase (Saz & Danbar et 
al, 1975) 
Interruption of Microtubular 
function (Lacey et al, 1988) 
Chloride Channel opener at 
GABA mediated intemeurans 
(Duce & Scott et al, 1985) 
Inhibition of phosphorylas-
phosphatase (Bueding et al, 
1970) 
MIF = Microfilaricidal, MAF = Macrofilaricidal (adulticidal) 
2.6.2 Transmission control (Infection control) 
If transmission can be reduced there will be reduction in new infections and 
then completely cessation can be achieved. Since there is no non-human 
reservoir of W. bancrofti, and only a very minor animal reservoir of B. 
malayi that probably plays little or no role in transmission to humans, the 
interruption can be achieved in 3 ways: a) By reducing and uhimately 
eliminating the reservoir of Mf through treating the human population, (b) 
By reducing contact between humans (especially Mf carriers) and mosquito 
vectors and (c) By combining these above two approaches. However, 
specific strategies for controlling transmission of infection will differ from 
one endemic area to another, which depends on the local parasite-vector 
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situation, existing health care, infrastructure and availability of funds, and 
local cultural attitudes. 
2.6.3 Through chemotherapeutic agents 
The available three drugs (DEC, IVM and ALB) have now been shown by 
intensive investigation to be safe and effective microfilaraicides for mass 
treatment to control transmission. These include both old (DEC) and new 
(IVM and ALB) antifilarials. Single dose DEC reduce blood Mf levels and 
comparable to that efficacy of IVM as effectively and to the same long 
lasting degree as the previously recommended 12 day course of DEC. The 
discovery of the concurrent treatment using two drugs; single doses of DEC 
and IVM is significantly more effective against Mf than use of any of the 
drugs alone. Moreover, the marked microfilaricidal effectiveness of these 
regimens makes them suitable for annual treatment designed to control 
transmission immediately, and in the longer term, to prevent morbidity. 
There is also evidence that wide spread use of such drugs, particularly DEC, 
is effective in reducing the incidence of clinical lymphoedema (Ottesen et 
al., 1985) probably because they can sterilize or kill a proportion of the adult 
worms. 
2.6.4 Through prophylactic agents 
Until recently the macrofilaricidal action of drugs against human lymphatic 
filarial parasites have been notoriously difficult to assess. However, 
investigations in Brazil have recently revolutionized the study of lymphatic 
filarial worms by ultrasound techniques to visualize adult W. bancrofti in the 
lymphatics with their 'movement' which is known as the "filarial dance 
sign" (Dreyer et al., 1994). This makes the situation possible to visualize the 
"nests" of worms with motile and alive and to remove them surgically. 
Single dose ("spaced dose") DEC given at weekly; monthly or 6 monthly or 
yearly intervals has been used for many years especially in Pacific Islands 
and Indonesia (Kimura et al, 1985; Partono et al., 1984; Laigret et al , 
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1980). More frequent single-dose DEC regimens (Week or monthly) has 
also been used and found effective in decreasing Mf prevalence and density. 
However, advantage over yearly or tri annually was not very much 
advantageous. For bancroftian filariasis administrations of repeated single 
dose in four or five yearly resulted in decrease in Mf density of 78% and 
97% respectively and decrease in Mf prevalence of 57% and 86% 
respectively, when measured 1 year after the last treatment. In Malayan 
filariasis 2 annual administrations of single dose DEC resulted in a decrease 
in Mf density of 81% and Mf prevalence of 75% which almost equivalent to 
those for individuals treated with single doses of DEC and followed 
sequentially for 12 months or more (Ramu et al., 1996). Killing of 50% of 
adult worms could be achieved using single dose of 6 mg/kg of DEC but 
higher dose did not produce additional macrofilaricidal action (Dreyer et al., 
1992). 
For many endemic areas where infections with O. volvulus or L. loa are co-
endemic with those of W. bancrofti, the use of DEC is avoided because of 
induction of severe and dangerous adverse reactions by rapid killing Mf. 
Therefore, two approaches are recommended throughout the world: 
1) Once-year "single dose" treatment (for 4-6 years) with either: 
a) Two drug regimen (optimal): IVM (200 ng/kg body weight) co-
administered with either DEC (6 mg/kg) or ALB (400 mg) or 
b) One-drug regimen: DEC (6 mg/kg) alone. 
DEC fortified salt (0.2 - 0.4% w/w) substituted for regular cooking salt for 6 
- 12 months. For the endemic zone having onchocerciasis or loiasis coexist 
with bancroftian filariasis the recommended drug regimen is: 
2) Once yearly: single dose administration (for 4 -6 years) of either -
a) Two-drug regimen (optimal): IVM (200 ^g/kg) + ALB (400 mg/kg) 
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b) Or two drug, single dose yearly regimen of IVM + DEC was found to be 
much more effective (trial in Papua New Guinea) and revealed >90% 
reduction in Mf density one year after treatment. The prevalence decreased 
progressively after two annual treatments, achieving 85% reduction in 
treated communities. Reduction in transmission indices further 
substantiated the efficacy of the control strategy (Bocharie et al., 1997). 
2.6.5 Morbidity (disease) control 
Even after elimination of Mf, the adult parasites, as well as opportunistic 
infection like bacterial and fungal infections may continue to induce 
lymphatic pathology and consequent morbidity. After transmission control it 
is essential to take care of morbidity control with regards to damaged, 
lymphoedematous limbs, as these remain susceptible to secondary bacterial 
and fiingal super infections. 
Recently, worldwide revised strategy for control and elimination of LF has 
been laid down by WHO which includes treatment of patients individually 
with drug including vector control, when practicable. 'Mass distribution' in 
place of older approaches, which are based on 'selective treatment', 
diagnosed individually to have microfilaraemia. 
2.6.6 Immunoprophylactic studies in filariasis 
Development of vaccine against filarial infection can act as additional 
measure to the existing therapeutic and vector control methods in the control 
of this disease. The main hurdles in the development of antifilarial vaccine 
are the strict primate specificity of W. bancrofti, the paucity of parasite 
material, the diversity of clinical manifestation and their associated complex 
immune responses, lack of clear understanding on host-parasite interactions 
and the mechanisms involved in protective immunity. However, in the past 
few years, the information generated in immuno-epidemiological studies, 
correlated with observations in experimental animals suggests that a filarial 
vaccine is feasible. 
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2.7 Effect of antifilarial treatment on the immune responses 
Since effective treatment of the adult parasites is currently unavailable for 
most filarial infections, treatment is primarily directed at the Mf. However 
the response to treatment depends on the clinical manifestations of the 
filarial infection. The reason could be the result of reduction in parasite 
burden, which ultimately reduce the sensitizing antigenic load. Patients with 
symptoms such as filarial fevers, lymphangitis but without microfilaraemia 
when treated with antifilarial showed remarkable improvement in 
symptoms. But in contrast treatment of Mf positive individuals with DEC or 
IVM causes rapid death of Mf and release of parasite antigens and often 
results in acute inflammatory reaction. Microfilaraemic individuals are often 
reluctant to seek therapy because of these reactions but treatment is essential 
to interrupt transmission of the parasite in the community. The 
immunopathology seen to develop within 1^ ' few weeks after treatment of 
microfilaraemic patients includes increased levels of blood eosinophils, 
circulating eosinophil derived proteins phosphocholine containing antigens 
in the serum and circulating microfilarial ES antigens. Significant increase 
in serum antifilarial IgG level also occurs within two weeks of treatment. 
However filaria specific IgE antibody remained unchanged or become 
variable. In some patients IgG and IgE are elevated in response to antigens 
which are unrecognized by the host before treatment (Lammie et al, 1988) 
and these antibodies are specially developed to high microfilarial densities. 
This suggests that treatment results into exposure of hidden antigens. 
Longitudinal studies before and after antimicrofilarial chemotherapy have 
also been used to study the effect of Mf and their product on T-cell 
reactivity. Specific increase in T-cell responses to filarial antigens have been 
observed 3 - 6 months after treatment in Mf positive patients with B. malayi, 
W. bancrofti infections. When lymphocyte proliferation was examined (two 
weeks after treatment), a generalized immune-suppression was observed, 
this was perhaps from the release of PC containing or other suppressive 
microfilarial antigens. Similar studies have been interpreted as supporting 
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the hypothesis that Mf derived products is important in suppressing 
lymphocyte reactivity (Lai et al 1987). However verification is required to 
prove the hypothesis. 
Various studies have shown that there was gradual decrease in filarial 
antibody titres and an initial increase followed by a gradual decrease in 
filarial antigen titres after DEC therapy (Malhotra and Harinath, 1984). 
Kumiawan et al (1995) showed a differential decline of filaria specific IgGi, 
IgG4 and IgE antibodies in B. malayi infected patients after DEC therapy. 
Circulating filarial antigen levels have been reported to vary during and after 
chemotherapeutic intervention (Weil et al. 1988; Day et al. 1991). Weil et al. 
(1988) reported the persistence of parasite antigenemia despite reduction of 
Mf counts, which may be a result of the sub-lethal effects of drug on the 
adult worms. Zeng et al (1991) reported a progressive decrease of filarial 
antigen levels in patients who remained amicrofilaraemic after treatment but 
which then increased with recurrence of Mf This indicated the presence of 
active infection either due to re-exposure to the infection or relapse due to 
parasites that survived the treatment. Thus from the existing information it 
seems that a clear understanding on the role of IgE, IgGi and IgG4 responses 
in parasite-infected individuals is essential in relation to parasite clearance 
and the recurrence of the infection. It seems possible that immediate 
hypersensitive responses are important effector mechanisms for eliminating 
parasite. Individuals with persistent microfilaraemia often mount adequate 
immediate hypersensitive responses. But it is not known whether, alterations 
in antifilarial antibodies following antifilarial treatment will enhance or 
reduce the take of infection or provide favorable environment for the 
existing or newly entered parasites to react with host defense system. 
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3.1 Materials 
3. t.l Chemicals 
All the chemicals, immunochemicals and immunoreagents used in the 
study were reagen: grade and obtained from different reputed 
vendors. 
3.1.2 Animals 
Jirds (Meriones unguiculatus; originally obtained from Liverpool 
school of Tropical Medicine, London, U.K.) and Mastomys concha 
(originally the GRA strain of the species was obtained through the 
courtsey of late Prof. G. Lammler, Director, of Institute fur 
Parasitologic, Giessen, Germany, 1974) were from colony of Central 
Drug Research Institute National Laboratory of Animal Centre 
(CDRI-NLAC), Lucknow, India. They were maintained under 
standard temperature, humidity and photoperiod (12 hours light and 
12 hours dark) conditions of CDRI-NLAC. Jirds were fed on standard 
pellet diet (Maharashtra Chakan and oil Mills, Pune, India), While M 
coucha were fed on pellet diet supplemented with dried shrimps, ad 
libitum. The animals had free access to drinking quality water. All the 
animals were handled and used humanely following CDRI 
Institutional Animal Ethics Guidelines (Figs. 1.6 & 1.7). 
3.1.3 Pireparation of solutions and reagents 
All the solutions and reagents used in the study are mentioned in the 
Appendix. 
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Fig. 1.7 Meriones unguiculatus (Gerbil) 
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3.2 Methods 
3.2.1 Maintenance of B. malayi infection in M. coucha and M. 
unguiciilatus (jird) 
The present work was carried out in laboratory developed filarial 
infection which was maintained in a rodent animal model M. coucha 
and B. malayi (a human lymphatic filariid) transmitted through black 
eyed susceptible strain of ^. aegypti mosquitoes (obtained through 
the courtsey of Prof. W. W. McDonald, Liverpool School of 
Tropical Medicine, London , U. K., 1972 ). 
3.2.2 Rearing and breeding oiA. aegypti colony 
Black-eyed susceptible strain of 4^. aegypti is the intermediate host 
of 5. malayi in laboratory. The mosquitoes were reared and bred in 
an insectarium maintained at 25 - 27°C temperature and 80 ± 5% 
humidity. The adult mosquitoes were kept in nylon mesh cages and 
fed on glucose solution soaked in cotton. Time to time female 
mosquitoes were fed on normal M. coucha to promote egg laying. 
The cages containing blood fed mosquitoes were provided with 
glucose solution. A beaker containing water was also kept in the 
cage for egg laying. The eggs were layed after 40 hrs blood feeding 
separated and stored in a container at same temperature and 
humidity. Eggs can be preserved in such condition for 3 - 4 months. 
Whenever needed the eggs were taken out and used for mosquito 
development. Eggs were transferred to enamel bow] containing tap 
water. The larvae hatch out in the water within 24 hrs and these 
were provided with yeast and powder dog bix. The larvae usually 
took about 8-10 days to become pupae, which ultimately developed 
into adult mosquitoes within 48 hours. Thus the whole cycle under 
controlled climatic conditions was used to complete in 22 - 25 days. 
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3.2.3 Feeding of mosquitoes on Mf positive M coucha 
B. malayi infected M. coucha showing 100 - 200 mf/10 cmm of 
blood were used as donors. The feeding of mosquitoes on donors 
was carried out between 12 noon & 1:00 P.M. The donor M coucha 
was immobilized in a wire netting cage, which was put into the 
mosquito cage having 2 - 3 hrs, starved mosquitoes. After feeding of 
mosquitoes, (which took 1 hr), the donor animal was removed and 
mosquitoes were provided with glucose as mentioned above. In 9 -
10 days time the Mf in the mosquitoes developed into infective 
larvae (L3). 
3.2.4 Isolation of L3 from mosquitoes 
On the 9th or 10th day of feeding, the mosquitoes were paralyzed 
and crushed gently in 4 - 5 ml of 0.6% insect saline (IS) and 
transferred to Baerman's apparatus filled with lukewarm IS. It was 
allowed to stand for half an hour. The L3 released from the 
mosquitoes were travelleld through the muslin cloth and settled 
down at the bottom of the tube. These were then collected by 
opening the pinchcock and washed with IS several times. The larvae 
were counted and used immediately for inoculation to animals. 
3.2.5 Inoculation of L3 to M. cowc/ia/jirds 
M. coucha, the multimammate rate (GRA strain Germany) is 
susceptible to B. malayi is being maintained in the animal house of 
Central Drug Research Institute for the last 25 years. The animals 
were kept in plastic cages and housed in a room maintained at 22 -
24°C temperature and were provided with standard rodent diet and 
water ad libitum. 6 - 8 weeks old male M. coucha and jird were 
inoculated with 100 L3 subcutaneously and 200 L3 intraperitoneally 
respectively, Establishment of successful infection was examined by 
preparing blood smear slide of tail blood after 90 day of infection. 
50 
Materials and Methods 
Animals showing 50 - 100 mf/10 cmm were selected for 
experiments. 
3.2.6 Assessment of Infection 
Infected animals were examined for appearance of Mf in the 
peripheral blood on day 120 and there after monitored at 15 days 
intervals. 10(1 of tail blood was taken between 12 noon and 1.00 pm, 
smeared in clean glass slide and dried for over night. Dried smears 
were dehaemolysed with tap water dried and stained with Leishman 
stain. Mf were counted under microscope. 
3.2.7 Parasite extract preparation for fractionation 
3.2.7.1 Isolation of Mf and adult worms ofB. malayi from jirds 
Mf were recovered from peritoneal cavity of jirds harbouring 5 - 6 
months old infection. The peritoneal fluid collected was passed 
through 5^m porosity of membrane filter as described by Fletcher et 
al., (1986). Mf in filter were dislodged in 0.1 M PBS kept at 37 °C. 
These Mf were washed 3 - 4 times in sterile PBS by centrifuging in 
ice cold 4 °C at 2000 rpm for 10 - 15 min. and stored at -20 °C for 
fliture use. Adult's worms were also isolated from the peritoneal 
cavity and washed several times in PBS and stored at -20 °C till 
further use. 
3.2.7.2 Preparation ofMfand adult worm soluble somatic extract 
B. malayi adult worms and Mf recovered from jirds were used for 
extract preparation. Soluble extracts of the parasites were prepared 
using the method of Hamilton et al., (1981). Briefly the worms were 
crushed in a Porter Elvejhm tissue grinder in PBS followed by 
sonication at 10 Kc for 10 min with 60-second intervals after every 
stroke of 60 second. Homogenate thus obtained was centrifuged at 
5000 rpm for 30 min at 4 C. The supernatant was collected and 
protein content was estimated by Lowry et al., (1951). Mf extract 
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was prepared as described above except that Mf were directly 
sonicated in PBS. 
3.2.8 Fractionation of B. malayi adult worm and microfilaria! 
extracts by Sephadex G-200 column chromatography 
3.2.8.1 Sephadex G-200 Column Preparation 
Fractionation of extracts of adult worms and Mf was performed 
according to the method of Egwang et al, (1988) using Sephadex G-
200 column chromatography Sephadex G-200 (Pharmacia Chemical 
Co. USA) is a cross linked Dextran (Poly a-1 , 6 D-anhydro 
glucopyranose) (Protein separation range: 5 - 800 kDa for globular 
protein and 1 - 200 kDa for linear protein). Sephadex G-200 was 
allowed to swell in 0.0 IM PBS pH 7.2 for overnight at 4 °C. After 
swelling the gel suspension was washed with PBS 3 - 4 times till it 
becomes clear. Degassed the gel suspension to remove any air 
bubble trapped in the suspension. The tapering end of the column 
was first sealed with glass fiber and then filled the column with 
suspension gently to avoid trapping of air bubble. Running length of 
the column was 47 cms and the top was leveled with a piece of 
sponge and then poured with some buffer (2"). Elution volume was 
calibrated by adding Blue Dextran (2mg/ml) prepared in 0.0 IM PBS 
to make sure how much volume of PBS was required to elute Blue 
Dextran 2x10^ kDa band completely. Flow rate was adjusted to 3 
ml/15 minutes. 
3.2.8.2 Elution of parasite extract from column 
The measured protein (16 mg/ 2 ml volume) of the extract was 
loaded and started collecting the fractions. Absorbance of the 
fractions collected was immediately read at 280 nm in UV-
spectrophotometer. The fractions were collected till the absorbance 
at 280 nm became static showing absorbance 0.05 or below. Three 
major peaks were obtained. The protein in peaks was estimated 
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according to the method of Lowry et al., (1951). These fractions 
were kept at -20 °C till further use. 
Three major peaks obtained were named as BmA-I, BmA-II and 
BmA-III of BmA and Bm^4f-I, BmMf-II and BmMf-III of BmMf 
Three batches of each extract were fractionated separately. Each 
peak from three different batches of each extract were pooled and 
used for the study (Fig. 2.1). 
3.2.9 Selection and grouping of animals 
Mf positive animals harboring around 5 months old infection and 
were showing progressive rise in microfilaraemia were selected for 
study. These were grouped mto 4 (Table 1.3). Each group consisted 
of 8 - 16 animals. Normal and healthy animals of same age and sex 
were also taken and grouped into four groups. Two replicates for 
each experiment were carried out. 
Table l.S Selection and grouping of animals 
Group 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
No. of animals 
16 
8 
8 
8 
16 
8 
8 
8 
Animals 
Infected (Inf) 
Infected Treated (Inf-T) 
Infected Treated-Remfected (Inff-R) 
Infected-Reinfected (Inf-R) 
Normal (N) 
Normal-Treated (N-T) 
Normal Treated Infected (NT-I) 
Normal-infected (N-I) 
3.2.10 Preparation and administration of antifilarials into animals 
Groups II and III (infected animals) and Groups VI and VII (normal 
animals) were treated with DEC at 150 mg citrate/kg through i.p. 
route or ALB at 50 mg / kg / day s.c. The agents were administered 
five consecutive days. Fresh solution was prepared daily before 
administration (Figs. 1.8 &1.9). 
3.2.11 Assessment of antifilarial efficacy 
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Fig. 2.1 Fractionation of B. malayi adult worm (A) and Microfilaria (B) 
extract by Sephadex G-200 column chromatography 
Column length: 47cm; Diameter: 1.5; Flow rate: 3ml/15 min. 
Materials and Methods 
3.2.11.1 Assessment of microfilariddal efficacy 
Microfilaricidal activity of the agents was evaluated according to 
method of Lammler & Wolf (1977). Microfilarial counts in lO-cmm-
tail blood were made just before start of treatment and thereafter at 
weekly intervals till day 63. Alteration in Mf count in relation to day 
0 (before treatment) was expressed as percent change in 
microfilaraemia. 
3.2.11.2 Assessment of adulticidal efficacy 
Macrofilaricidal efficacy was evaluated according to method of 
Chatterjee et al, (1992). On day 63 the animals were sacrificed and 
various organs like heart, lungs, testes and lymph nodes were 
isolated and teased. The worms recovered were examined under 
microscope for motility and mortality. 
3.2.11.3 Assessment of efficacy of drugs on female reproductive potential 
Fonale parasites \^ 'ith empty uteri or the uteri containing dead or 
degenerated stages of developing parasites including Mf were 
considered ar, sterilized worms. The percent sterilization of female 
worms was calculated from the number of worms sterilized out of 
the total live female worms recovered. All the surviving female 
worms recovered from each animal were teased individually on glass 
slice and examined the intra-uterine contents under microscope. 
Percent mortality of worms was calculated as follows. 
C-E 
% Mortality of worms = _ 
C- Number of worms recovered from control animals 
E- Number of worms recovered from experimental animals 
3.2.11.4 Re-exposure with L3 
Animals of group III, and VII were exposed to L3 on day 30 since the 
start of the treatment. Group VIII received L3 on the same day. 
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3.2.11.4.1 Parasitological profile 'y^ '^^ C 
(i) Assessment of microfilaraemia '"-i!:i"(;ra Uiii^«i^i^ 
Mf count was assessed and monitored as described earlier 
(3.2.11.1) 
(ii) Assessment of worm burden 
The worm burden wad assessed as mentioned earlier (3.2.11.2). 
3.2.12 Blood cell counts 
3.2.12.1 Determination of total leucocyte counts (TLC) 
Total leucocyte counts (TLC) were made by standard method using 
Naubauer counting chamber as described by Dacie et al., (1970). 
Briefly, 5|il of tail blood from each animal was taken and diluted 
(20 times) in Turks fluid and kept for 5 min. counting chamber was 
than charged with 10|LI1 of the diluted blood and cells were counted 
under the microscope in WBC counting area. 
3.2.12.2 Determination of differential leucocyte counts (DLC) 
Thin tail blood slides were prepared on the clean glass slides. These 
were air dried, fixed in methanol and stained with 5% Giemsa stain 
for 1 hr. Slides were then washed thoroughly with tap water, dried 
and cells were observed under microscope using oil immersion 
objective (lOOX). Lymphocyte, polymorphonucleocytes, 
eosinophils, monocytes and basophils were counted and percentage 
of cells was calculated from the total cells counted (100 - 200 cells) 
at each occasion. 
3.2.13 Humoral immune responses 
3.2.13.1 Serum isolation 
Blood from animals of various study groups was collected from 
retro-orbital plexus or heart. The blood was allowed to clot at 37 °C 
for 2 hrs. Serum was isolated from the clot, centriftiged at 2000 rpm 
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for 10 min. in a refrigerated centrifuge and kept at -20 °C, for use in 
ELISA and immunoblot analysis. 
3,2.13.2 Optimization of various reagents 
Working concentrations of various reagents i.e. parasite extracts and 
their fractions, serum and antibody conjugated with HRP were 
optimized by checkerboard titration. Table (1.4A & B) 
Table 1.4 Optimization of various reagents for determination of 
serum IgG (A) and IgM (B) 
(A) 
Parasite 
extract/Fraction 
BmA 
BmA-I 
BmMf 
BmMf-I 
Cone. 
0.1 
0.25 
0.01 
0.01 
Serum 
dilution 
1:50 
1:100 
1:100 
1:100 
Antimouse IgG 
conjugated witli HRP 
(dilution) 
1:5000 
1:5000 
1:5000 
1:5000 
(B) 
Parasite 
extract/ 
Fraction 
BmA 
BmA-I 
BmMf 
BmMf-I 
Cone. 
(^g/ml) 
2.5 
2 
5 
2.5 
Serum 
dilution 
1:200 
1:200 
1:200 
1:200 
Antimouse 
IgM 
conjugate 
dwith 
biotin 
(dilution) 
1:20000 
1:20000 
1:20000 
1:20000 
Streptavidin 
Conjugated 
with HRP 
(dilution) 
1:500 
1:500 
1:500 
1:500 
3.2.13.3 IgG and IgM antibody determination by ELISA 
Filaria specific IgG/IgM was detected in sera of animals following 
the method described by Voller et al., (1976) with some 
modifications to suit our conditions. 
ELISA plates/strips (Nunc-Denmark) were coated with antigens 
prepared in carbonate buffer (0.06M; pH 9.6) and kept for overnight 
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at 4 °C. After overnight incubation the unbound antigen was drained 
out and washed twice with PBS (0.0 IM; pH 7.0). Now wells were 
dispensed with 1% BSA (150 |il/well) prepared in PBS for blocking 
the unoccupied sites and incubated at 37 °C for 90 min. After 
incubation, wells were washed thrice with PBS-T20 (washing 
solution) and sera (100 jil /well) diluted in BSA-T20 were added and 
incubated for 90 min at 37 °C followed by 3 - 4 washes with PBS-
T20 and again incubated with antimouse IgG labeled with HRP at 37 
°C for 90 min. For determination of IgM biotinylated secondary 
antibody (i.e. anti mouse) was put after reaction with serum and 
incubated for 90 min at 37 °C. This was followed by washing and 
incubation with streptavidin conjugated with HRP for 90 min at 37 
°C 
The plates were washed thrice with PBS-T20. The substrate 
containing OPD (0.8mg/ml) and H2O2 was then added. Color 
developed within 15-20 min was stopped by adding 5M H2SO4 (25 
^il/well) and absorbance was measured spectrophotometrically at 492 
nm on ELISA reader (Molecular devices USA). 
3.2.14 Cell mediated immune responses 
3.2.14.1 Lymphocyte transformation test (LTT) 
LTT was performed according to the method of Lammie & Katz 
(1988) using lymph nodes and spleen cells of M coucha. 
Isolation of lymph node/spleen cells 
Whole procedure was performed in aseptic condition. Lymph nodes 
and spleen of animals were removed and placed in medium RPMI-
1640 containing antibiotics. Cells were isolated by crushing of 
lymph nodes and spleens separately in medium. Cells were isolated 
from tissue by passing through 100-|im-nylon filter, centrifuged and 
suspended in complete medium (10% PCS). The viability of cells 
was checked using 0.1% Trypan blue exclusion method and viable 
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cells were counted. Finally cell concentration was adjusted to 
IxloVml in complete RPMI-1640 medium. Cell suspension was 
dispensed in 96-well tissue culture plate (Nunc-Rosklide Denmark), 
each well-contained 2x10^ cells in 200)il volume in Triplicate. BmA 
(lO i^g/ml), BmA-I, BmA-II, (5^g/ml), Con-A (lO^ig/ml), PHAP 
(5^g/ml) were used for the proliferative response of the cells. After 
o 
adding these reagents the plates were kept at 37 C in 5% CO2 
atmosphere for 72 hrs. Cells in medium only were kept for control. 
After 72 hrs of incubation the cells were pulse labeled with ''H-
thymidine (l|ici/well) and again kept for 18 hrs at the same 
atmosphere. Cells were harvested using cell harvester (Dynatech 
Multimash 2000) and the extent of thymidine incorporation was 
measured by P-counting in a liquid scintillation counter (1217-
Reckbeta Wallace Finland). The results were expressed as 
stimulation index, which is calculated by dividing mean CPM of 
stimulated culture with mean CPM of unstimulated culture. 
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3.2.14.2 Determination of cytokines (IL-10, IL-6, TNF-a, IFN-y) by 
ELISA 
Table 1.5 Optimization of various reagents for determination of 
cytokine 
Cytokine 
IL-6 
IL-10 
IFN-y 
TNF-a 
Capture 
antibody 
(^g/ml) 
Mouse anti IL-6 
mab 
(4) 
Mouse anti IL-
10 mab 
(5) 
Mouse anti IFN-
Y mab (1.25) 
Mouse anti 
TNF- a mab (3) 
Detection 
Antibody 
(|iig/ml) 
Mouse anti IL-6 
antibody (2.5) 
Mouse anti IL-10 
antibody (1.25) 
Mouse anti IFN-
Y antibody (5) 
Mouse anti TNF-
a antibody (2) 
Extra 
avidin 
conjugated 
with HRP 
1:200 
1:200 
1:200 
1:200 
Procedure 
The procedure was followed according to manufacturer's instruction. 
Briefly, the ELISA plates (Nunc Denmark) were coated with capture 
antibody [mouse anti IL-6/TNF-a /IFN-y/IL-lO monoclonal 
antibody] prepared in Sodium phosphate (0.1 M; pH 9.0 and kept at 
4 °C for overnight. After incubation the unbound antibodies were 
removed and washed twice with PBS (0.0IM; pH 7.0). Blocked the 
non binding sites by incubating the plates with 3% BSA (150|il/well) 
prepared in PBS (0.0IM; pH 7.0 at room temperature for 90 min 
followed by four washes with PBS-T20. Cell culture supematants 
were dispensed (100|il/well) and kept at 4 °C for overnight. After 
incubation, wells were washed 5 times with PBS-T20 and optimum 
concentration of detection antibody was added and incubated for 90 
min. at room temperature (28 - 30 °C). Plates were then washed 5 
times with PBS-T20 and incubated with extravidin conjugated with 
HRP diluted in BSA-T20 at room temperature for 90 min. Washing 
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step was repeated as above and rest of the steps which included 
incubation with substrate, development of colour, stoppage of 
reaction and measurement of O.D. were same as described earlier for 
determination of IgG/IgM. 
3.2.15 Molecular responses of host 
3.2.15.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis of 
crude extracts of B. malayi adult worms, microfilariae and their 
fractions. 
SDS-PAGE was run according to the method described by Laemmli 
et al., (1970) using vertical gel electrophoresis (Techno source 
India). Clean glass plates (1mm thickness) were fitted in the vertical 
gel caster apparatus using spacers and gaskets. These assembled 
plates were then transferred into the main apparatus and sealed with 
0.6 % agarose to make buffer tank. Running gel of 12.5% or 10% 
and stacking gel of 3.7% were used. Immediately after pouring 
stacking gel Teflon comb was inserted and allowed to polymerize 
the gel. The comb was then removed and tank was filled with 
running buffer (pH 8.3). Samples prepared in sample buffer were 
loaded into the wells. Commercially available standard molecular 
weight markers (Prestained SDS-7B 26.6 - 180 kDa) were also 
loaded into the wells for the determination of approximate molecular 
weight of the protein bands (Arnold et al., 1969). Samples were 
allowed to run at 15 mA in stacking gel. The current was increased 
to 25 mA and kept constant while the samples was in running gel. 
The current was than discontinued and the gel was removed from the 
glass plates gently, rinsed in TDW and then either subjected to 
Coomassie blue staining or Silver Staining. 
(a) Silver Staining 
Silver staining is very sensitive for visualization of protein. To 
visualize the small amount of protein, the gel was stained with silver 
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Stain as per method of Wray et al, (1981). Briefly, after completing 
the electrophoresis the gel was immersed in 50% methanol and 10% 
acetic acid solution. After one hour the gel was immersed first in 5% 
methanol ft)llowed by immersion in silver nitrate solution ft)r 15 
minutes. The gel was washed 3 - 4 times with TDW and dipped in 
developer till the bands were visible. The reaction was stopped by 
1% acetic acid. 
3.2.15.2 Western blotting of SDS-PAGE resolved components of BmA, 
BmMf BmA-I and BmA-II. 
Transfer of proteins from gel to NCP was done using electro blotting 
method as described by Towbin et al., (1979). Gel containing freshly 
resolved antigen protein was immersed in blotting buffer for 10 - 15 
minutes to equilibrate. In the meantime nitrocellulose paper 
(Millipore 0.22 \x.m porosity) was cut according to size of the gel and 
immersed in the same buffer. Blotting cassette of gel-NCP was 
prepared. Now the cassette was immersed in blotting buffer tank and 
the current was set at 200 mA for 4 - 5 hr at 4 °C. The extent of 
transfer of antigen bands was optimized on the basis of transfer of 
pre-stained marker protein. After 4 - 5 hours NCP was removed, 
made a marked on the NCP to indicate the direction of travel of 
protein, dried and stored at -20 °C till use. 
3.2.15.3 Immunoblotting of resolved components of BmA, BmMf, BmA-I 
and BmA-II with sera ofM. coucha. 
Immuno reactivity of resolved blotted bands was analyzed using sera 
of M coucha according to method described by (Murthy et al., 
1999). NCP was stripped into 2 mm wide and washed with TBS 
(lOmM pH 7.4) in chambered incubation tray. Strips were incubated 
with 3% gelatin at 37 °C in water bath shaker for 1 hr or at 4 °C for 
overnight. Gslatin was washed 5 times with TBS and charged with 
optimum concentration of sera diluted in gelatin-TBS-T20 and 
61 
Materials and Methods 
o 
incubated at 37 C for 90 min. Strips were washed 5 times with TBS-
T20 (washing solution) and antimouse IgG-conjugated with HRP 
0 
was added (Optimum concentration) and incubated at 37 C for 90 
min as above. Substrate solution containing DAB prepared in TBS 
and H2O2 was added and incubated till the reactivity of the bands was 
visualized. Immediately after appearance of bands the reaction was 
stopped with tap water, and the strips were then dried and mounted 
on the drawing paper for analysis. 
3.2.15.4 Studies on DNA integrity in lymphocytes and splenocytes of M. 
concha infected with B. malayi and correlation with CMI 
(i) Selection offilaria infected animals 
Twenty-three animals were used for the study. Group 1, 2 and 3 
consisted of 11, 4 and 8 animals having early ( 1 - 2 months), mid (6 
months old infection with circulating Mf) and chronic (more than 12 
months old infection) stages of infections, respectively. Animals of 
Groups 2 and 3 were microfilaraemic. Group 4 and 5 comprised 3 
and 8 animals, respectively. While cells of Group 4 were treated 
with 200|iM of H2O2 for 10 min for positive control, cells of animals 
of Group 5 were left as such and served as negative control. 
(ii) Alkaline gel electrophoresis 
Lymphocytes/splenocytes from animals were isolated as described 
earlier (3.2.14.1) were adjusted to concentration range 1 - 2 
million/ml and were loaded in wells of electrophoretic apparatus 
(Genei, Banglore India) in minimum volume. Each well was then 
sealed with 0.5% of low melting agarose to prevent the leakage of 
cell when immersed in lysing solution (Singh et al., 1988). Now the 
whole gel was put in lysing solution (1% Sodium Sarcosinate, 2.5 M 
NaCl, lOOmM Na2-EDTA, lOmM Tris pH 10; and 1% Triton X-100) 
at room temperature for 1 - 2 hrs to lyse the cells and allowed the 
DNA for unfolding. The gel was then removed from lysing solution 
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and placed on a horizontal gel electrophoresis unit filled with freshly 
prepared electrophoretic buffer (ImM Na2-EDTA & 300mM NaOH) 
(1 cm above the gel). The gel was further allowed to set in high pH 
buffer (pH 13) for 30 min. Electrophoresis was carried out at 25 volt 
o 
at 4 C for 1 hr to compensate the heat produced during alkaline gel 
electrophoresis. After electrophoresis the gel was washed gently to 
remove alkali and detergents in 0.4 M tris with pH 7.5 before 
subjected to EtBr staining. After 5 min, the gel was stained with 20 
|ig/ml EtBr prepared in distilled water and the observed under UV 
and recorded in UV gel documentation (UVP-Gel documentation 
UK). 
(iii) Assessment of CMI response using Lymphocyte 
transformation test (LTT) 
LTT was performed using lymphocytes/ splenocytes of the M. 
coucha having different stages of B. malayi infection as described 
earlier (3.2.14.1). 
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4.1 Effect of DEC treatment followed by re-infection with 
B. malayi 
4.1.1 Parasitological observations 
4.1.1.1 Level of microfilaraemia 
Fig. 3.1 shows the effect of DEC on the course of microfilaraemia in Inf-T 
and InfT-R animals. A marked reduction in Mf count (80%) was recorded 
in Inf-T animals on day 7 since the start of the treatment (P<0.01), which 
thereafter remained suppressed significantly (P<0.01 - <0.05) till day 63 of 
treatment (day of sacrifice). Inf animals (control) showed continuous 
increase till day 63 of treatment. The level of microfilaraemia in InfT-R 
animals increased significantly (P<0.05) within a week after challenged 
with L3, which thereafter crossed the pre-treatment level (P<0.01) by day 
63. However in Inf-R animals the level of Mf did not increase and 
remained comparable with the pre-treatment level throughout the 
observation period. 
4.1.1.2 Status of worm burden 
DEC treatment failed to kill adult worm in Inf-T. However around 40% of 
the female parasites recovered were sterile. The percent recovery of 
developing stages of larvae from InfT-R animals was higher (6.5) as 
compared to their counterparts Inf-R animals (2.75). None of the sex and 
age matched NT-I showed any developing stages of the worm after one-
month (30 days of L3 exposure) of infection. N-I animals of same age and 
sex showed 3.5% developing stages (Table 1.6). 
4.1.2 Blood cell counts 
Table 1.7 shows TLC and DLC in pre- and post-treated and subsequenf/y 
infected and re-infected M. coucha. 
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Tables 
Table 1.6 Effect of DEC treatment followed by re-infection with B. malayi one 
month after the beginning of the treatment: Status of worm burden. 
Group 
Inf (16) 
Inf-T (8) 
InfT-R(8) 
Inf-R (8) 
NT-I (8) 
NI(8) 
Male 
7±3.4 
6.6±1.5 
5.8±1.0 
6±7 
-
-
Percent worm recovery (Mean ± SE) 
Female 
18.33±5.6 
16.33±3.5 
23.8±5.7 
8.5±1.1 
-
-
Sterile 
Female 
39.1±3.3 
43.13±3.9 
48.4±2.8 
12.97±1.9 
-
-
Developing 
stages 
-
-
6.5±0.9 
2.75±0.8 
-
3.5±0.4 
Total parasite 
(Adult) 
25.33±8.8 
23±4.6 
29.5±6.7 
20±1.4 
-
-
Number in parenthesis = No. of animals 
Table 1.7 Effect of DEC treatment and re-infection with B. malayi: 
Blood cell counts of M. concha. 
Group 
Inf(16) 
Inf-T (8) 
Inf-TR (8) 
Inf-R (8) 
N(16) 
N-T (8) 
NT-1 (4) 
N-I (4) 
TLC 
(MeaniSE) 
30765 ±1755 
16492 ±993 
19836 ±1109 
15972 ±986 
8790 ± 493 
10021 ±690 
9872 ± 540 
19542 ±1832 
Lymphocytes 
42 ±1.4 
46.3 ±2.1 
49.78 ±1.8 
43.6 ±1.9 
43.2 ±2.3 
45.4 ±0.8 
42.9 ±0.7 
45.2 ±0.8 
DLC (MeaniSE) 
Neutrophils 
54.8 ±2.3 
53.6 ±2.3 
50.1 ±1.9 
56.3 ±0.8 
56.8 ± 0.07 
54.6 ±2.3 
57.1 ±1.8 
54.8 ±1.8 
Eosinophils 
3.2 ±0.09 
01 ±0.003 
0.12 ±0.005 
0.1 ±0.003 
0.0 
0.0 
0.17 ±0.008 
0.27 ± 0.008 
Number in parenthesis = No. of animals 
Results 
Significant decrease (P<0.05) in TLC and eosinophil counts in Inf-T 
animals occurred on day 30 since the start of DEC treatment. When the 
treated animals were exposed to L3 (InfT-R) there was a little increase in 
TLC as compared to Inf-T ones but eosinophil counts remained same. 
However in Inf-R animals both TLC and eosinophil counts significantly 
decreased as compared to Inf animals and a small decrease was observed 
when compared with the counts of InfT-R animals. Treatment in age and 
sex matched normal animals (N-T) did not alter TLC and eosinophil 
counts. Animals of NT-I showed significant increase in both TLCs and 
eosinophils. A significant increase in TLC and eosinophil counts was also 
observed in sex and age matched N-I animals as compared to the values of 
normal healthy (N) animals. 
4.1.3 Antibody levels 
4.1.3.1 IgG 
Antibody levels were detected in all the experimental and control animals 
using crude extracts of BmA, BmMf and their fractions. These were 
obtained as described under Materials and Methods. Three major peaks of 
BmA (BmA-I, BmA-II and BmA-III) and BmMf (BmMf-I, BmMf-II and 
BmMf-III) obtained are shown in Fig 2.1 A and 2.IB. In the present study 
BmA-I, BmA-II, BmMf-I along with BmA and BmMf have been used as 
antigens. 
Levels of filarial specific IgG directed against B. malayi adult, Mf and 
their fractions in uninfected and infected animals treated with DEC and 
subsequently exposed to L3 are presented in Figs. 4.1 - 4.4. After one-
month of treatment with DEC in Inf animals, the IgG levels directed 
against BmA, BmA-I and BmMf increased significantly (P<0.05) (Figs. 
4.1 A - 4.3A). The levels of anti-BmA antibody in Inf-T animals remained 
almost same till the day of sacrifice. However there was a decrease in 
levels of anti BmA-I and anti-BmMf IgG in Inf-T animals by the second-
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month of treatment. However a little increase in anti-BmMf-I IgG was 
observed on second-month of treatment. While in InfT-R animals the anti-
BmA and anti-BmMf-I IgG levels were comparable to levels of Inf-T 
animals (Figs. 4.1 A & 4.4A), anti-BmA-I and BmMf IgG levels increased 
(Figs. 4.2A & 4.3A). Animals of Inf-R animals, the IgG levels detected 
against all the parasite preparations were found to be significantly 
decreased (P<0.01) (Figs. 4.1 A - 4.4A). 
It was observed that level of anti-BmMf and BmMf-I IgG antibodies in N 
animals remained same when compared with 0-day IgG level (Figs. 4.3B & 
4.4B). In contrast sex and age matched N-I animals showed significantly 
high (P<0.01) anti-BmA and BmA-I antibodies as compared to Inf-R 
animals (Figs. 4. IB & 4.2B). In these animals (N-I), anti-BmMf and anti-
BmMf-I IgG levels were comparable to Inf-R animals (Figs. 4.3B & 4.4B). 
NT-I animals showed significantly low (F<0.05) level of anti-BmA, anti-
BmA-I and anti-BmMf as compared to InfT-R (Figs. 4.IB, 4.2B & 4.3B). 
The anti-BmMf-I IgG levels in these animals (i.e. NT-I animals) was 
comparable to their counterparts, InfT-R animals (Fig. 4.4B). 
4.1.3.2 IgM 
IgM antibody levels in infected and normal animals are presented in Figs. 
5.1-5.4. 
Treatment with DEC did not alter the anti-BmA, anti-BmA-I, BmMf and 
BmMf-I IgM levels in any of the animals except age and sex matched 
animals of group N-I (Figs. 5. IB - 5.4B). In these animals anti-BmA-I IgM 
antibody level was found to be significantly increased (P<0.05) (Fig. 5.2B) 
as compared to Inf-R animals. This indicated that the primary infection 
increased the IgM. 
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Results 
node cells: Con-A 1.0; BmA 1.58; BmA-14.6; BmA-II 1.82; (SI: of spleen 
cells: Con-A 1; BmA 1.58; BmA-I 3.09; BmA-II 1.87). 
The response of lymph node cells of NT-I animals to Con-A, BmA, BmA-I 
and BmA-II were significantly high (SI: Con-A, 16.41; BmA, 6.16; BmA-
I, 2.9; BmA-II, 2.69;) as compared to sex and age matched normal animals. 
But the cells of N-I animals responded very high (SI: 10.31) to Con-A. 
Cells of NT-I animals responded weakly to Con-A or parasite preparations. 
4.2.5 Level of Cytokines (IL-6, TNF-a, IFN-y, IL-10) 
Table 2.3 shows level of cytokines (IL-6, TNF-a, IFN-y and IL-10) in 
animals treated with ALB and subsequently re-exposured to L3. 
IL-6 
ALB treatment caused significant (P<0.01) increase in IL-6 production in 
Inf animals. However in InfT-R animals there were a decrease in IL-6 
production as compared to Inf-T animals, which was however comparable 
to Inf animals. Inf-R animals showed almost similar level of IL-6 
production as observed with Inf animals. Though in N-T animals the IL-6 
production was found to be increased significantly (P<0.01), re-infection in 
group (N-T) further increased the level of IL-6 production. Sex and age 
matched N-I animals showed significantly (P<0.01) elevated level of BmA 
and LPS stimulated IL-6 production as compared to normal animals, 
indicating increase in IL-6 production was due to infection. 
TNF-a 
Treatment of infected animals did not alter the TNF-a production. Re-
infection in these animals (Inf-T) resulted in apparent decrease in TNF-a 
production but statistically insignificant. Re-infection in infected animals 
(Inf-R) increased the LPS and BmA stimulated TNF-a production as 
75 
Results 
compared to Inf-T and InfT-R animals. Age matched NT-I and N-I animals 
showed comparable level of TNF-a production. 
iFN-r 
IFN-y production in treated (Inf-T) animals was registered to be increased 
significantly, (P<0.01) which was however, decreased after re-exposure 
(animals of InfT-R). Reinfection in infected animals (Inf-R) up regulated 
BmA and LPS stimulated IFN-y production. Treatment with ALB itself 
increased IFN-y production (P<0.01) in normal animals. In NT-I animals 
BmA and LPS stimulated IFN-y production was found to be increased 
significantly (P<0.05) as compared to N animals. But there was no 
apparent increase in IFN-y production in N-I animals. 
IL-10 
Treatment caused increased (P<0.01) IL-10 production by lymph node cells 
of Inf animals. However in InfT-R animals the BmA and LPS stimulated 
IL-10 production remained more or less same when compared with animals 
of Inf group but unstimulated cells of InfT-R animals produced high IL-10 
as compared to Inf animals. In Inf-R animals though BmA stimulated IL-10 
production was decreased (statistically not significant) but LPS stimulated 
IL-10 production remained same. Exposure with L3 in normal treated 
animals (N-T) caused elevated level of IL-10 production. However 
infection in normal animal (N) failed to do so. 
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sera. InfT-R sera identified larger number of bands (30, 32, 33, 48, 52, 58, 
62, 64, 73, 79, 97.4 kDa). Among these 62 kDa showed strong reactivity. 
Inf-R sera reacted moderately with 54, 97.4 kDa and weakly with 68 and 
73 kDa antigen bands. Normal sera reacted with 54, 97.4 kDa molecules. 
N-T sera reacted moderately with 54, 56 and 97.4 kDa and weakly with 79 
kDa. NT-I sera identified 32, 54, 62, 66, 68, 70, 73, 79, 97.4 kDa 
molecules, of which 54 and 79 kDa molecules showed moderate reactivity. 
Age matched N-I sera reacted almost same antigen bands. However they 
showed moderate reactivity with 41.5 - 46.3 kDa molecules. 
Trend of reactivity pattern of BmA-II antigen molecules with sera of N-T, 
NT-I and N-I animals was more or less identical but reacted with 40 kDa 
and below. With Inf and Inf-T sera 17.5 kDa molecule was reactive. InfT-R 
sera reacted with 8.5, 20.1, 28, 32, 40 kDa molecules, of which 28 and 32 
kDa bands were moderately reactive. Sera of Inf-R reacted strongly with 28 
kDa, and weakly with 8.5, 32, 36.5, 38 kDa molecules. 
Inf sera recognized lesser number of bands (23, 38,40.5, 54, 56, 62, 64, 66, 
70, 160, >200 kDa) of BmMf as compared to BmA. One-month post-
treated sera reacted with 20.1, 62 and > 170 kDa antigen bands. However, 
more reactive bands were identified with sera of second-month post-treated 
sera (62, 64, 66 and 97.4, >170 kDa). InfT-R sera reacted with 20.1, 22, 62-
200kDa of BmMf Inf-R sera identified 23.5, 62-66, 97.4 and >200 kDa. 
Sera of normal animal showed reactivity with 52 and 66 kDa molecules. N-
T sera reacted with only 66 kDa (weakly reactive). However NT-I sera 
reacted with 25, 56, 62, 64, 66 and 70 kDa bands. Sera of age and sex 
matched N-I animals reacted with 25, 40, 56, 62, 64, 88 kDa and >200 kDa 
antigen molecules. 
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Fig. 9.1 Effect of ALB treatment followed by re-infection with B. malayi 
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Fig. 9.2 Effect of ALB treatment followed by re-infection with B. malayi 
one- month after the beginning of the treatment: Level of BmA-I 
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Legends 
N = Normal Inf = Infected 
N-T = Normal treated Inf-T = Infected treated 
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Fig. 9.3 Effect of ALB treatment followed by re-infection with B. malayi 
one- month after the beginning of the treatment: Level of BmMf 
specific IgM antibodies in infected (A) and normal (B) M. coucha 
Legends 
N = Normal 
N-T = Normal treated 
NT-I = Normal treated infected 
N-I = Normal-infected 
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N = Normal 
N-T = Normal treated 
NT-I = Normal treated infected 
N-I = Normal-infected 
'P<0.05(Inf vs. Inf-T) 
Inf = Infected 
Inf-T = Infected treated 
Inf-TR = Infected-treated reinfected 
Inf-R = Infected-reinfected 
Figures 
25 
20 
X u 
•o -_ 
.£ u 15 I ^ 
.2 u 10 
• Con-A 
DBmA-I 
^ W I 
• BmA 
• BmA-II 
rW 
5 fcii 
* * 
N N-T I-T 
25 1 
20 
1^ 
.S u 15 
3 5 10 
E £-
55 
• Con-A HBmA 
DBmA-I n BmA-II 
N 
tttb 
N-T 1 
Animal 
* * 
** 
B 
I-T 
Fig. 10.1 Cell proliferative response of lymph node (A) and spleen cells (B) of 
normal M. coucha to different stimulants: One-month post ALB 
treatment 
Legends 
N= Normal Inf= Infected 
N-T = Normal treated Inf-T = Infected treated 
"P<0.01 (NT vs. IT) for Con-A and BmA 
Figures 
X 
25 
20 
^ 15 
I* 10 
N 
• Con-A BBmA 
DBmA-I DBmA-II A 
** 
* * 
• 
N-1 N-T 
Animal 
** 
^ 
NT-I 
.S w 
g ^ 
1 i 
25 
20 
15 
10 
5 
0 
B Con-A 
QBrnA-I 
r l l 
N 
• BmA 
DBmA-II 
i i 
N-l N-T 
Animal 
h 
fa 
NT-I 
B 
Fig. 10.2 Cell proliferative response of lymph node (A) and spleen cells (B) to 
different stimulants: L3 infected M. coucha one-month post 
infection {= Second-month post ALB treatment) 
Legends 
N= Normal 
N-T = Normal treated 
NT-I = Normal treated infected 
N-I = Normal-infected 
"P<0.01(N vs. NT), (N vs. N-I), (N vs. NT-I) for Con-A 
and (N vs. NT-I) for BmA-I 
Figures 
25 1 ^Con-A BBmA 1 S 
20 
II 
= S 10 
5 
0 + 
BmA-I DBmA-U 
1^ 3 
rr l^ 
** 
* 
L3 ** 
fl ft 
-R I-T 
Animal 
IT-R 
20 u 
.S U 
10 
5-
• Con-A SBmA 
* * 
* 
i-R I-T rr-R 
Animal 
Fig. 10.3 Effect of ALB treatment in B. malayi infected M. coucha followed 
by re-infection with B. malayi: Cell proliferative response of lymph 
node (A) and spleen cells (B) to the stimulants before treatment, 
One month post-treatment and one-month post-re-infection 
(=Second-month post-treatment) 
Legends 
Inf = Infected 
Inf-T = Infected treated 
Inf-TR = Infected-treated reinfected 
Inf-R = Infected-reinfected 
'*P<O.OI (Inf vs. Inf-T) for BmA, (Inf vs. Inf-TR), for Con-A 
and (Inf vs. Inf-R) for BmA-I 
Figures 
MW 
kDa 
MW 
kDa 
Fig. 12.7 Reactivity of BmA-II with ALB treated and re-infected 
M. coucha sera 
Lanes 
a Infected 
b Infected treated (I^ ^ month) 
c Infected treated reinfected 
d Infected reinfected 
Lanes 
a Normal 
b Normal treated (I ^ ' month) 
c Normal treated infected 
d Normal infected 
Figures 
MW MW 
a b c d 
r 
kDa 
-170 
- 97.4 | - 66 
- 45 
- 36 
- 29 
^ 2 4 
- 20.1 
- 14.2 
e 
Fig. 12.8 Reactivity of BmMf crude extract with ALB treated and re-
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Tables 
Table 2.4 Immunoblot reactivity profiles of B. malayi antigens by sera of M. concha treated with DEC and 
subsequently re-exposed to L3 of homologous infection. 
Group 
1 
2 
4 
5 
6 
7 
8 
B m A 
Mol. w t (kDa) 
>200, 170, 
160,97.4,70, 
66,48,29,24, 
22.5,22,14.2 
62,50,46,35,34 
62 
170,160,22 
45 
100 
200.97.4,85, 
70,44,38,32,22 
28,22 
190,180,58 
29 
100.88,2^.29.56.62 
44,24 
>200,100,97.4,88, 
70,68,66,64,62,56 
22.5,6.8 
>200,97.4,88,70, 
68,66,58,29 
React ivi ty 
-1-+ 
+ 
++ 
+ 
+++ 
++ 
+ 
+-H-
+ 
+ 
+ 
++ 
+ 
+ 
+ 
B m A - l 
M o l . wt 
(kDa) 
97.4,73,66,62,52 
60,32-29,14.2 
97.4 
73,66,62 
45,32 
97.4,29 
79,73,64,62, 
60,58,52,32 
97.4,54 
73,68 
97.4 
68,66,62,56,54 
54 
97.4,73,70,68, 
66,62,56,54,48,30 
41.5-46.3,29 
97.4,79,73, 
68,66,62,58,54 
Reactivi ty 
+-^  
+ 
+-t 
+ 
+++ 
+-r 
+ 
++ 
+ 
+ 
+ 
++ 
+ 
++ 
+ 
B m A - I I 
Mol . wt 
(kDa) 
38.8.5 
36,35,24.22 
38,30 
28 
32,28 
-
28.17.5 
28 
38,30 
36.5,8.5 
38 
38 
38,30,28 
-
38.32 
-
React ivi ty 
++ 
-r 
++ 
+ 
++ 
-
4-
+++ 
++ 
+ 
+ 
+ 
++ 
-
++ 
-
B m M f 
Mol . wt 
(kDa) 
>2U0, 70.66.64, 
62,40.5,25 
160,56.54.38 
> / / o , 974 . 
66, 64. 62, 
20.1. 
-
>170.20.1 
-
66,64,62. 
97.4,22 
97.4,66-62.23.5 
>170 
66,52 
>170 
>170,100,97.4, 
64 
62,25 
>200,88,64,62, 
56.40. 
2,5.23 
Reactivity 
++ 
+ 
++ 
-
++ 
-
-r 
++ 
+ 
+ 
++ 
++ 
+ 
++ 
+ 
+++ = Strongly reactive; ++ = Moderately reactive; + = Weakly reactive 
Number underlined = with 1 ^ ' month treated sera; Number italics = with 2" month treated sera 
Tables 
Table 2.5 Immunoblot reactivity profiles of ^. malayi antigens by sera of M, couclta treated with ALB and 
subsequently re-exposed to L3 of homologous infection. 
Group 
1 
2 
3 
4 
5 
6 
7 
8 
BmA 
Mel. wt (kDa) 
>200,l 70,160,97.4. 
85,23,22,14.2 
50,48,36 
]M.,50,48.29,23, 
22,17.5-6.8 
97.4.85,62.50,48. 
36.14.2 
62 
24 
-
28^2 
-
-
29 
97.4,88.66,^ 
-
23 
200,100,66, 
29,20.1,17.5 
97.4,88,70,68,66, 
58,29,22.5, 6.8 
-
Reactivity 
++ 
+ 
-1 + 
+ 
+++ 
++ 
-
-H-+ 
-
-
+ 
+ 
' 
++ 
+ 
+ 
-
BmA-I 
Mol. wt 
(kDa) 
97.4,73,66,62,52 
60,32-29,14.2 
97.4 
64,62,58, 
52,50,45 
62 
97.4, 73, 52, 
79, 64,58, 
48, 33,32,30 
97.4,54 
73,68 
-
97.4,54 
97.4,56,54 
79 
79,54 
97.4,73,70, 
68,66,62,32 
41.5-46.3,29 
79,58,73,97.4, 
68,66,62,58,54 
Reactivity 
++ 
+ 
++ 
+ 
+++ 
-H-
+ 
++ 
+ 
-
+ 
++ 
+ 
++ 
+ 
++ 
+ 
B:nA-II 
Mol. wt 
(kDa) 
38.8.5 
36,35.24.22 
17.5 
-
32.28 
-
40,20.1.8.5 
28 
38,32 
36.5.8.5 
38 
40.32 
-
38.32 
-
38.32 
-
Reactivity 
++ 
t-
H + 
-
•i-'-
-
+ 
+-H-
+ 
+ 
+ 
-
+ 
-
+ 
-
BmMf 
Mol. wt 
(kDa) 
>200.70.66,64 
62.40.5.23 
160,56.54,38 
>170, 
97.^,66,64.52, 
20.1 
25.24.2j 
>2U0-62 
22,20.1 
-
>200,97.4, 
62-66,23.5 
-
-
66,52 
66 
-
70,66,64, 
62,56,25 
-
>200,88,64, 
62,56,40,25 
-
Reactivity 
H — 
-
-1—1-
-V 
++ 
+ 
-
-H-
-
-
+ 
j -
-
-r 
-
++ 
-
+-1-4- = Strongly reactive; ++ = Moderately reactive; + = Weakly reactive 
Number underlined = with 1^ ' month treated sera; Number italics = with 2" month treated sera 
Results 
4.3.4 Studies on DNA integrity in lymphocytes and spienocytes of M, 
coucha infected with B. malayi and correlation with CMI 
4.3.4.1 Migratory pattern of DNA of lymphocytes and spienocytes of M. 
coucha with ^. malayi 
Table 2.6 shows the migratory pattern of DNA of lymphocytes and 
spienocytes of M. coucha (uninfected and B. malayi infected) by alkaline 
gel electrophoresis. Lymph node cells from normal animals (Group 4) 
when treated in vitro with H2O2 showed migration of DNA (1.5cm) 
indicating DNA damage (positive control). In contrast, unexposed lymph 
node or spienocytes (Group 5) did not show any migration of DNA 
depicting no DNA damage. In contrast all the 6 chronically infected 
animals of Group 3 (more than 12-months old) showed DNA damage in the 
form of smear in both spienocytes (1.17cm ± 0.75) and lymphocytes 
(0.65cm ± 0.28). However, 3 of the 4 animals (Group 2) harbouring 6-
month old infection with Mf in the peripheral blood showed substantially 
low damage in DNA of spienocytes (0.3cm ± 0.09) only. Interestingly, 9 
out of 11 animals (Group 1) having early stage of infection (1 -2 -months 
old infection) with nc peripheral Mf showed no damage in DNA of 
spienocytes or lymphocytes. However of extent of damage in DNA of 
lymphocytes of two animals of Group 1 was comparable to the damage 
observed in Group 2 animals. The results showed that apparently there was 
a direct correlation between extent of DNA migration and duration of 
exposure (Table 2.6). 
4.3.4.2 CMI response 
In general proliferative response of botli spienocytes and lymphocytes as 
assessed by LTT was ahnost similar. The proliferative responses of cells 
from chronically infected animals to both BmA and mitogen were 
significantly suppressed CP<0.01). Interestingly, the response of 
spienocytes or lymphocytes of animals harbouring early and mid stage of 
81 
Results 
infection to parasite or mitogen was also either suppressed or unresponsive 
when compared to normal uninfected animals (Table 2.7). 
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Fig. 13.1 Electrophoretic migration of DNA of lymph node and spleen 
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malayi infection 
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Fig. 12,1 Reactivity of BmA crude extract with DEC treated and re-
infected M. coucha sera 
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Fig. 12.2 Reactivity of BmA-I with DEC treated and re-infected 
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Fig. 12.3 Reactivity of BmA-II with DEC treated and re-infected 
M. coucha sera 
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Fig. 12,4 Reactivity of BmMf crude extract with DEC treated and 
re-infected M. coucha sera 
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Fig. 12.5 Reactivity of BmA crude extract with ALB treated and re-
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Fig. 12.8 Reactivity of BmMf crude extract with ALB treated and re-
infected M. coucha sera 
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Discussion 
induced type2 associated immune responses have been linked to the 
protective function and the formation of filaria-mediated granulomas. 
However, what happens when this highly regulated, and often beneficial, 
type-2 immune response becomes chronic, improperly controlled, or 
exaggerated during infection in not clearly understood. 
The present study revealed that anti-BmA antibody levels were not 
significantly affected by treatment. While some animals showed alteration in 
antibody level, some of the animals appeared to have achieved steady state 
antibody levels. Presumably, treatment is associated with the release of large 
quantities of antigens from dying parasites, leading simultaneously to the 
formation of antibody and to antibody consumption. Although more detailed 
study is required to understand the dynamics of antibody formation and 
subsequent effect of antifilarial treatment upon this process. 
The ablation of parasite specific immune responses in filariasis implies that 
the immune reactions most affected are those that may allow chronic 
persistence of filariae within their host. Portono et al., (1985) suggested that 
comparison of immune responses before and after parasite clearance might 
identify effective anti-parasite responses without the danger of inducing long 
term pathology, as it is known that chemotherapy of LF is not pathogenetic 
for long period i.e. chemotherapy does not lead to the development of 
permanent disability. 
Defined antigens are urgently needed for diagnosis and vaccine 
development. Over the past few years, a number of filarial antigens have 
been identified, both from the cuticular surface and from somatic and 
secreted preparations (Maizels et al., 1987), but there is little detailed 
information on such molecules. A combination of immunological, structural, 
and functional data is clearly essential if appropriate parasite antigens are to 
be selected for diagnostic or prophylactic use. An understanding at this 
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molecular level is also necessaiy to establish how filarial parasites are so 
successful at evading effective immune responses for long periods of time. 
In humans it has been found that many treated patients appeared to have 
steady state of antibody levels (Lammie et al., 1988). In Western blots 
studies of the recognition of specific antigens, DEC treatment led to 
recognition of new antigen specificities, defined by the appearance of new 
bands of 66 and 13 kDa. The significance of observation is not clear. The 
lack of appearance of new bands in some of the infected animals following 
treatment suggests that treatment per se does not necessarily lead to the 
expression of anti-microfilarial immunity. Consequently direct evidence of 
increased cellular responsiveness to filarial antigens in such treated animals 
might be likely to redevelop patent infection. Lammie et al., (1988) 
demonstrated 66 and 12 kDa molecules to be reactive with sera of some of 
the Mf positive patient on western blots and related to be dependent on 
microfilaraemia. However they have also reported that in a large proportion 
of infected patients (but apparently have filarial antigen), specific responses 
were independent of microfilaraemia. However, Fletcher et al. (1986) have 
shown 22 and 18.5 kDa antigens present in adult and Mf 5. pahangi, were 
reactive with the sera of cats before the elimination of microfilaraemia, 
which became amicrofilaraemic thereafter. 
In the present study 28 kDa and 22 kDa antigens were found to be strongly 
reactive in infected and L3 re-exposed animals. Balloul et al., (1987) 
reported that 28 kDa and 22 kDa antigens were protective in mice and 
rodents against schistosoma. Contrary to this 45 kDa antigen band, which 
was lighted up in, infected DEC treated and L3 re-exposed has been reported 
for use in monoclonal antibody production (Sutanto et al, 1985). In the 
present study 62 kDa antigen expressed strongly when reacted with ALB 
treated, and subsequently re-exposed animal sera may be have protective 
function in relation to development of L3. The same molecular weight 
antigen has been reported to be reactive and developed as Gib-13 
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monoclonal antibody specific (Lai et al, 1987). Nevertheless, in our study 
we have found, 29 kDa molecules to be weakly reactive with sera of all the 
animals. Nevertheless parasite surface has received especial attention for 
identifying prominent and potentially protective antigens. 29 kDa molecular 
weight protein of B. malayi has been found to bear epitopes cross-reactive 
between different stages and species of filariae (Kaushal et al., 1982; 
Maizels et al., 1983). This antigen has close analogues in 29 - 30 kDa 
proteins from the adult worms of other lymphatic filariids, B. pahangi, B. 
timori and W. bancrofti. Interestingly, in the present study sera of normal 
and infected DEC treated animals also showed moderate reactivity with 29 
kDa molecules. Possibly this 29 kDa molecules were not only have filarial 
cross-reactive epitopes but might have epitope (s) directed towards DEC 
complexed host antigens which were not identified with the sera of 
completely normal animals. 29 kDa molecules have been used for 
monoclonal antibody production (Sutanto et al., 1985). Maizels et al., (1989) 
reported that 29 kDa is a glycoprotein and highly conserved between two 
species of Brugia. The unique feature of this molecule is that although its N-
linked oligosaccharides bind Con-A, this lectin does not bind with intact 
adult parasites, indicating that unlike mammalian cell surface, but like 
another nematode Trichenella spiralis, the glycan portions of the surface 
molecules are hidden (Ortega-Pierres et al., 1984). Nevertheless, the 29 kDa 
antigen is secreted by the parasites in vitro (Maizels et al., 1989). 
Sera of infected DEC treated animals reacted strongly with 45 kDa (near to 
43kDa). Freedman et al. (1989) using B. malayi L3 demonstrated reactivity 
of 43 kDa with endemic normals and suggested that this molecule may have 
prophylactic potential. However, Singh et al (1997) reported that 43kDa of 
all the three life stages of B. malayi (Mf, L3 and adult worms) was reactive 
with Mf positive subjects. It was suggested that the different pattern 
observed in the study and findings of Freedman et al (1989) could have been 
due to differences in the strains of W. bancrofti. Hence, we may expect that 
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45kDa molecule which was found to be strongly reactive may have 
protective potential. 
With BmA-II Inf-R sera reacted strongly with 28kDa band, whereas a 38 
kDa protein band was found to be reactive with all the sera of animals 
belonging to the study groups. 
As expected Inf sera recognized lesser number of bands with BmMf extract 
as compared to BmA and none of the antigens were strongly reactive with 
any of the sera. 
In the present study the profile of cytokines in the infected animals before, 
after treatment with antifilarials and subsequently after L3 exposure to the 
treated animals revealed the following findings: First, following treatment 
with DEC there was no alteration in the IL-6 and IL-10 levels in treated 
animals. However exposure with the L3 decreased IL-6 production 
significantly as compared to infected-re-infected animals. TNF-a and IFN-y 
levels in the treated animals were demonstrated to be increased after 
treatment in infected animals, however re-infection did not affect the levels 
of the cytokines. These finding are in accordance with the results obtained 
with bancroftian patients treated with DEC (Turner et al., 1994). The 
findings of the present study indicate that alteration in the cytokine profile 
was solely dependent of presence or absence of parasites as in DEC treated 
animals though dramatic fall in Mf counts occurred immediately after 
treatment the adult parasites were unaffected. Th2 cells produce IL-4 and IL-
10, which are reported to lead to parasite survival (Ravindran et al., 2001) 
and its magnitude correlates with the severity of disease. In contrast, ALB 
treatment led to significant increase in specific IL-10 and IFN-y levels in 
infected animals, while the post treatment level of TNF-a remained 
unaffected. However there was increasing trend in IL-6 production after 
treatment with ALB. Th2 cells produce IL-4 and IL-10, which are reported 
to lead to parasite survival (Ravindran et al., 2001) and its magnitude 
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Fig. 13.1 Electrophoretic migration of DNA of lymph node and spleen 
cells isolated from M. concha harbouring different stages of ^. 
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the parasite before the treatment. Nevertheless, proinflammatory cytokines 
are responsible for development of infection. Thus from the present study it 
is evident that proliferative responses of the cell populations and host 
cytokine responses positively or negatively may be fate of re-infection in 
antifilarial treated human hosts. To-date no evidence is available on early-
and late-acting immune events particularly involvement of cytokines 
following infections in antifilarial treated hosts. 
In immune system, cell death is an important step to maintain lymphoid 
homeostasis and avoid disease. It can occur through apoptotic or necrotic 
pathways. There are two morphologically and biochemically (Searle et al., 
1982; Arends et al, 1991) distinct modes of death in nucleated eukaryotic 
cells. These cells die not by a process of disordered dissolution but by one or 
other of two different sets of stereotyped reaction i.e. necrosis and apoptosis. 
Necrosis is associated with major perturbation in the cellular environment 
and has been regarded as a pathological response whilst apoptosis, which is 
an orderly process that proceeds through several morphological phrases 
(condensation and shrinkage of cells) has been observed in many instances 
where the death of the cell is not pathological but appears to be part of 
homeostatic regulation. 
Historically necrosis was recognized first which occurs as a result of 
complement attack, severe hypoxia, hyperthermia, lytic viral infection or 
exposure to a variety of toxins and respiratory poisons (Trump et al., 1981). 
These diverse lethal stimuli increase the permeability of the plasma 
membrane either through alterations in its structure (complement, viral lysis) 
or by failure of the cationic ion membrane pumps (hypoxia, respiratory 
poisons). Finally necrotic cells take up water and swell and burst releasing 
cytoplasmic contents in the surroundings, which are cytotoxic to other cells 
in the tissues this situation makes irreversible states. Several mechanisms 
have been suggested to account for the irreversible state. Evidences suggest 
that cellular depletion of ATP is associated with necrosis. However a fall in 
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ATP concentration alone is ineffective in inducing death in absence of extra 
cellular calcium or in the presence of other agents. Apart from this, 
generation of reactive nitrogen species (NO) in combination with super 
oxide anion by the cells have potent antimicrobial activity. 
Chronic exposure with any infectious agents or toxic substances is known to 
lead DNA damage in host's cells (Holzmuller et al., 2002; Awara, et al., 
1998). Our result shows for the first time a preliminary but definite 
fmdings/data that chronic stage of filarial infection may induce DNA 
damage in splenocytes or lymphocytes of B. malayi infected animals. The 
results were further supported when compared with H202-mediated DNA 
damage in lymphocytes or splenocytes of normal animals. However no such 
damage in DNA was observed in lymphocytes or splenocytes of animals 
harbouring early stage of infection. At present, in the light of our 
preliminary findings, it is apparent that DNA damage in the splenocytes or 
lymphocytes of the animals might have been the consequence of chronic 
parasite exposure, which led to cell necrosis as evidenced by smear 
formation /DNA tailoring. Murthy et al, (1994) reported focal necrotic 
regions in the lymphnodes and spleen. Histopathological observations in 
both human and animals with chronic filarial infection revealed the same 
findings. These data support the view that cell necrosis could be involved in 
hyporesponsiveness in filarial infected hosts. However these findings 
warrant further investigations. Recently Holzmuller et al., (2002) 
demonstrated NO-mediated cytostatic and cytotoxic effects on axenically 
grown and intracellular Leishmania amazonensis amastigotes which then 
consequent to activation of a pathway that was referred to as apoptosis - like 
process. Melino et al., (1997) have reported that NO could be able to induce 
necrosis as well as apoptosis. Whether such mechanism also plays a role in 
filariasis is not understood. Nevertheless genotoxic effects of parasites 
molecules in cells of filaria-infected animals need to be identified and 
monitored for understanding parasite biology and pathogenesis which may 
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provide valuable information for designing better therapeutic measures for 
cure and control of the disease. 
Thus from the present study it is concluded that 
In ALB treated and reinfected animals, increased BmA specific CMI and 
IFN-y production may be correlated with absence of (resistance to) 
reinfection. 
Slow and gradual decrease in filarial specific IgG in ALB treated (Inf-T) and 
no further appearance of IgG after re-infection correlated with the absence 
of reinfection. 
A prompt increase in filarial specific IgG in infected DEC treated (Inf-T) 
animals and no further alteration in IgG levels after reinfection supported the 
presence of developing stages of reinfection. 
Whereas 62 kDa molecule recognized by sera of ALB treated reinfected 
animals was correlated with development of resistance against reinfection, 
32 and 45 kDa bands recognized by sera of DEC treated reinfected animals 
correlated with the development of reinfection. However, 22 and 28 kDa 
molecules were identified with sera of Inf-R animals, which showed 
establishment of lesser no of worms. These antigens may be important for 
development of strategies for treatment/control modalities of the disease. 
DNA damage in splenocytes/ lymphocytes of animals harbouring chronic 
stage of B. malayi infection correlated hypo-responsiveness of cellular 
proliferative response of the host. 
Thus the results of the present study indicate that while DEC treatment may 
enhance recurrence of infection, ALB treatment may facilitate development 
of resistance against re-infection. 
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CHAPTER- 6 
Lymphatic filariasis is primarily a disease of the poor because of its 
prevalence in remote rural areas and in disfavored peri-urban and urban 
areas. LF is caused by nematode parasite species Wuchereria bancrofti, 
Brugia malayi and B. timori. It is transmitted through mosquitoes. 
Globally, LF is thought to be second leading cause of permanent and long 
term disability. Some 120 million people are infected worldwide, and the 
disease is endemic in more than 80 countries and territories. More than 
90% of cases with W. bancrofti and 10% of cases with B. malayi are 
recorded. The spectrum of lymphatic filariasis is analogous to leprosy. 
Microfilaria carriers with no signs and symptoms represent one pole and 
patients with elephantiasis and chronic lesions represent the other pole. 
Several strategies are currently being tried for control and eradication of 
filariasis but the main emphasis continues to be on vector control and 
chemotherapy. DEC, IVM and ALB are the antifilarials used in 
chemotherapy. Recently, the World Health Organization (WHO) in 
collaboration with GlaxoSmithKline launched a global LF elimination 
program with a drug combination approach consisting of treatment 
schedules with ALB + DEC or IVM. However, the most intriguing feature 
of the infection is its unpredictable recurrence after treatment. The reasons 
for this are not clear. For instance, it is not known whether a) the altered 
immune responses of the host following treatment with antifilarial(s) are 
able to provide conducive environment for re-infection, b) individuals 
become more vulnerable to acquiring infection or become resistant to re-
infection after a course or repeated courses of treatment, and c) prior 
exposure to antifilarial(s) alter the biology/infectivity of parasite. 
Unfortunately there have been no systematic studies to answer these 
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questions. The present study was therefore, aimed at investigating 
aherations in immune responses of the B. wfl/oyi-infected host after 
treatment with antifilarials and after re-infection of the treated host. This 
will help understanding the possible reasons involved in the recurrence of 
infection or resistance to therapy in human filariasis. 
The present study was carried out using M. coucha-B. malayi model 
comprising the main groups (Table as below): infected animals, infected 
treated animals, infected treated re-infected animals, infected re-infected 
and age and sex matched normal infected animals to see the effect of re-
infection in antifilarial treated animals on the modulation of acquired 
immunity with particular reference to parasitological, physiological and 
immunological responses of the host. 
Selection and grouping of animals 
Group 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
No. of 
animals 
16 
8 
8 
8 
16 
8 
8 
8 
Animals 
Infected (Inf) 
Infected Treated (Inf-T) 
Infected Treated-Reinfected (InfT-R) 
Infected-Reinfected (Inf-R) 
Normal (N) 
Normal-Treated (N-T) 
Normal Treated Infected (NT-I) 
Normal-infected (N-I) 
DEC at 150 mg citrate/kg or ALB at 50 mg / kg were given through i.p. 
and s.c. route, respectively. The agents were administered five consecutive 
days. Fresh solution was prepared daily before administration. 
Infected or normal treated animals were exposed to L3 on day 30 since the 
start of the treatment. 
Various parameters like parasitological, blood cell counts and 
immunological (humoral, cell proliferation and cytokines) responses of the 
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host before treatment, one month post-treatment and one-month post-
larval (L3) inoculation (= two month post-treatment) were carried out. 
The antibody response of pre- and post-DEC/ALB treated and 
subsequently re-infected animal sera samples were analyzed qualitatively 
with western blot of BmA and BmMf and Sephadex G-200 
chromatographic fractions of BmA. Experiments were also carried out to 
correlate DNA integrity using comet assay of lymph node and spleen cells 
of M coucha harbouring early, mid and chronic stages of B. malayi 
infection and cell proliferative response to filarial antigen and mitogen of 
the host. 
The salient findings of the present study are as follows: 
In contrast to control animals (Inf) a marked reduction in Mf count (80%) 
was found in Inf-T animals on day 7 since the start of the treatment, which 
thereafter remained suppressed till the day of sacrifice. The level of 
microfilaraemia in InfT-R animals increased within a week after challenge 
with L3, and crossed the pre-treatment level by day 63. However, the level 
of Mf in Inf-R animals did not increase and remained comparable with the 
pre-treatment level throughout the observation period. 
DEC treatment failed to kill adult worms. The percent recovery of 
developing stages of larvae from InfT-R animals was higher as compared 
to their counterparts Inf-R and N-I animals indicating that DEC treatment 
might be responsible for such enhancement in worm recovery. 
An inverse correlation between microfilaraemia and eosinophilia was 
found. Decrease in eosinophil counts was accompanied by removal of Mf 
from the circulation. 
Treatment with DEC in Inf-T animals caused increase in IgG levels 
directed against BmA, BmA-I and BmMf of which anti-BmA antibody 
levels remained almost unchanged till the day of sacrifice. In InfT-R 
animals the anti BmA and anti-BmMf-I antibody levels were comparable 
99 
Summary and Conclusions 
to levels of Inf-T animals, whereas in the Inf-R group, anti-BmA-I and 
BmMf IgG levels increased and the IgG levels against rest of parasite 
preparations decreased significantly. 
Treatment with DEC did not alter the anti-BmA, anti-BmA-I, BmMf and 
BmMf-I IgM levels in any of the animals except age and sex matched 
animals of group N-I. 
Treatment restored the proliferative response of cells of infected animals 
to Con-A and BmA-I, which however suppressed after reinfection. 
While DEC treatment in infected animals caused decrease in BmA and 
LPS stimulated IL-6 production, TNF-a production was found to be 
increased. In InfT-R animals BmA induced IL-6 production was further 
decreased but no further increase in the level of BmA induced TNF-a 
production was observed in these animals. In contrast LPS stimulated cells 
produced significant increase in TNF-a production. 
DEC treatment caused decrease in BmA induced IL-10 production in Inf 
animals. In InfT-R it further decreased. BmA induced IFN-y production 
was increased after treatment, which was again increased (more than 3 
times) after re-infection. 
Treatment with ALB in Inf animals resulted complete clearance of 
microfilaraemia and worms. Interestingly neither InfT-R nor NT-I animals 
showed developing stages of the parasites indicating prophylactic potential 
of ALB. 
The decrease in eosinophil counts in response to ALB treatment was less 
as compared to the effect of DEC. Re-infection in treated animals failed to 
increase the TLC and eosinophil counts. 
Treatment with ALB caused significant and gradual decrease in J^G 
directed against BmA, BmA-I, BmMf and BmMf-I till the day of sacrifice. 
Re-exposure with L3 in treated animals (InfT-R) caused further decrease in 
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anti-BmA, BmMf, BmMf-I IgG levels. In Inf-R animals, IgG levels 
increased significantly as compared to InfT-R animals. 
Treatment with ALB showed significant decrease in IgM levels directed 
against BmA, BmMf and BmMf-I in infected animals. Re-exposure of 
infected treated animals (InfT-R) caused significant decrease in anti- BmA 
and BmMf-I IgM antibody levels. However levels of anti-BmA-I and anti-
BmMf IgM in InfT-R animals remained unaltered compared to Inf-T. 
Inf-R animals showed increase in anti-BmA and anti-BmMf-I IgM 
antibodies. 
Like DEC, ALB also restored the proliferative response of both lymph 
node and splenocytes to all the stimulants, although the response towards 
Con-A was significantly high. Re-infection failed to further alter the 
proliferative response of the spleen cells or lymph node cells to the 
stimulants when compared with Inf-T group. Interestingly, cells of Inf-R 
animals showed significantly decreased proliferative responses to the 
stimulants. 
ALB treatment caused significant increase in IL-6 production in infected 
animals. However in InfT-R animals the IL-6 production was decreased 
when compared with value obtained in Inf-T animals but is comparable to 
the level of Inf animals. 
Treatment (ALB) did not affect the TNF-a production in infected animals 
but in InfT-R animals the production decreased. 
IFN-y production in ALB treated (Inf-T) animals was upregulated 
significantly, which however decreased after re-exposure (InfT-R 
animals). 
ALB treatment caused increased IL-10 production in Inf animals. 
However in InfT-R animals the level of BmA stimulated IL-10 production 
remained almost same when compared with Inf animals . 
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In Inf-R animals, BmA stimulated IL-6 and TNF-a production was 
comparable to Inf animals. Whereas re-infection up-regulated BmA 
stimulated IFN-y production in infected (Inf) animals, BmA stimulated IL-
10 production was found to be decreased. 
The present findings on the effects of DEC in B. malayi infected M. 
concha are in accordance with the reported observations in bancroftian 
patients treated with DEC. The following are the inferences made from the 
above results of the present study. Firstly, since Th2 cells produce IL-4 
and IL-10, which were reported to facilitate parasite survival and that the 
magnitude of response correlates with the severity of disease, the increase 
in IL-10 observed in InfT-R group in the present study clearly 
demonstrates that DEC treatment prior to re-infection facilitates the 
'takeVestablishment of the infection. Second, a quantitative relationship 
between the raised TNF-a levels and the development of re-infection was 
demonstrated for the infected or infected treated animals. Third, while 
DEC decreased IL-10 production, ALB elevated IL-10 production. This 
suggests that the adult antigens available after ALB induced adult parasite 
killing, stimulate IL-10 production. This is fiirther supported by the 
observation that IL-10 production is not stimulated by DEC treatment 
since DEC is not an efficient adulticidal agent. Fourth, IL-6, TNF-a and 
IFN-y increased significantly after treatment with DEC in normal 
uninfected animals while IL-10 remained decreased. The significance of 
this observation to establishment of or resistance to re-infection is not 
readily evident, but the effect is clearly a direct effect of DEC rather than 
DEC 'opsonized' parasite antigen effect since no antigen is available in 
these animals. Fifth, apparently elevated levels of IFN-y in re-infected 
animals correlated with the lesser number of the parasite establishment. 
This finding is in contrast to DEC treatment in infected animals, which 
facilitated the development of re-inoculated L3 as evidenced by 
development of more number of parasites. 
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Sera of infected DEC treated animals reacted with a lesser number of 
bands of BmA and BmA-I. The range of reactive bands increased after re-
infection showing strong reactivity with 32 and 45 kDa molecules of ether 
BmA and or BmA-I. Though Inf-R sera also identified lesser number of 
bands they reacted strongly with 22 and 28 kDa molecules of BmA and or 
BmA-II. 
Sera of all the categories of animals reacted either moderately or weakly 
with 38 kDa and below of BmA-II antigen. 
Sera from Inf-T animals (ALB treatment) reacted with 6.8 - > 160 kDa 
BmA antigen molecules. InfT-R sera reacted strongly with 62 kDa 
molecule of BmA and BmA-I was strongly reactive. 
Sera of Inf-R animals reacted strongly with 22 and 28 kDa molecules of 
BmA. 
The level of DNA damage in the splenocytes and lymphocytes of M. 
concha (uninfected and B. malayi infected) was assessed on the basis of 
migration of DNA. The chronically infected animals showed DNA 
damage in both splenocytes and lymphocytes, however, 75% of animals 
harbouring mid stage of infection with Mf in the peripheral blood showed 
substantially low damage in DNA of splenocytes only. Interestingly, 
animals of early stage of infection with no peripheral Mf showed no 
damage in DNA of splenocytes or lymphocytes. Apparently there was a 
direct correlation between extent of DNA damage and duration of 
exposure of infection. Further DNA damage appeared to be correlated 
with the proliferative response of splenocytes or lymphocytes of animals 
to filarial extract and mitogen. 
Thus from the present study it is concluded that 
In ALB treated and reinfected animals, increased the BmA specific CMI, 
which may be correlated with absence of (resistance to) re-infection. 
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• 
Slow and gradual decrease in filarial specific IgG in ALB treated (Inf-T) 
and no further appearance of IgG after re-infection correlated with the 
absence of re-infection. 
A prompt increase in filarial specific IgG in infected DEC treated (Inf-T) 
animals and no further alteration in IgG levels but re-suppression in cell 
proliferation after re-infection supported by the presence of developing 
stages of re-infection. 
Whereas 62 kDa band recognized by sera of ALB treated reinfected 
animals was correlated with development of resistance against re-
infection, 32 and 45 kDa bands recognized by sera of DEC treated 
reinfected animals correlated with the development of re-infection. 
However, 22 and 28 kDa bands were identified with sera of Inf-R animals, 
which showed establishment of lesser number of worms. These antigens 
may be important for development of strategies for treatment/control 
modalities of the disease. 
DNA damage in splenocytes/lymphocytes of animals harbouring chronic 
stage of B. malayi infection correlated hyporesponsiveness of cellular 
proliferative response of the host. 
Thus the results of the present study indicate that while ALB treatment 
may facilitate development of resistance against re-infection, DEC 
treatment may enhance recurrence of infection, 
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Appendix 
1. Column Chromatography 
(i) Sephadex G-200 4 - 5 g 
(ii) Phosphate Buffered Saline 0.01 M pH 7.2 
NaCl 0.13 M 
Na2HP04 8 mM 
KH2PO4 1.5 mM 
Dissolved separately in 1 liter TDW and adjust pH 7.2 with 
1 N NaOH 
(iii) Dextran Solution 
Dextran 0.2% 
PBS 0.01 MpH 7.2 
2. SDS-PAGE 
(i) Loading buffer pH 6.8 
Tris-HCl 0.125 M 
SDS 4 % 
Glycerol 20 % 
p-Mercaptoethanol 0.2|I 
Bromophenol Blue 0.2 mg 
TDW up to 10.0 ml 
Aiiquoted and stored between -40 C - 80 °C 
(ii) Solution I 
Acrylamide 30 gm 
Bis- acrylamide 0.8 gm 
Dissolved separately in TDW and made up to 100 ml and 
Stored at 4 °c 
(iii) Solution II (0.75 M Tris - HCl; pH 8.8) 
Tris- 9.07 gm 
SDS 200 mg 
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Dissolved in TDW. Adjust pH 8.8 with IN HCl. Made up to 
100 ml and stored at 4 °C 
(iv) Solution III (1.25 M Tris- HCl; pH 6.8) 
Tris 15.142 gm 
SDS 100 mg 
Dissolved in TDW. Adjust pH to 6.8 with IN HCl made up to 
100 ml with TDW and stored at 4 °C 
(v) 10% SDS 
SDS lOgm 
Dissolved in 100 ml TDW and stored at room temp. 
(vi) 10% Ammonium persulphate (APS) 
APS 2gm 
Dissolved in 20 ml TDW and stored at - 20 °C 
(vii) Tris -Glycine Electrophoresis Buffer pH 8.3 
Tris - Base 25 mM 
Glycine 250 mM 
SDS 1% 
Dissolved (a) and (b) in 300 ml of TDW, then check pH (8.8) 
Made up to 400 ml with TDW. Add (c) and mixed and kept at 
room temperature. 
(viii) Coomassie blue staining solution 
0.1% of Coomassie Brilliant Blue (R-250) was prepared in 40% 
of methanol and 10%) glacial acetic acid 
(ix) 
(X) 
Destaining solution 
Methanol: 
Acetic acid 
Silver staining 
(a) Silver Sjolution 
Ag NO3 • 
NaOH 
NH3 
40% 
10% 
0.58 M 
0.9 M 
8M 
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Titrate AgNOs in solution of NaOH and NH3 and made up to 50 
ml 
(b) Developer 
Citric acid 0.047 M 
HCHO 37 - 40 % 
250 ^1 of Citric Acid and 25 )il HCHO in 50 ml of TDW 
(c) Stop Solution 
Glacial acetic acid 1% 
(d) Destaining Solution for Silver Staining 
NajSjOj 1.5M 
CUSO4 0.15 M 
NaCl 0.6 M 
NH4OH 0.9M 
Mix 100 ml of Na2S203 with an equal volume of solution of 
CUSO4, NaCl, NH4OH (1:1:1) 
3. ELISA 
(i) Bicarbonate Buffer (pH 9.6) 
NasCOs 1 M 
NaHCOa 1 M 
Dissolve in 100 ml of T.D.W separately 
(ii) Coating Buffer (for Cytokine estimation) 
NaHP04 0.01 M 
(ii) PBST-20 (pH7.2) 
PBS O.OIM 
Tween-20 0.05 % 
(iii) Blocking Buffer (1 % BSA) 
BSA 1gm 
Dissolve in 100 ml PBS at 37 °C 
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(iv) 
(V) 
Citrate Buffer 
Citric acid 
Na2HP04 
Substrate preparation 
Citrate buffer 
OPD 
H2O2 
(pH 5.0) 
0.09 M 
0.2 M 
25 ml 
0.1% 
38% 
4. Solution and medium for cell proliferative 
assay (LTT) 
(i) Preparation of RPMI-1640 Medium (pH 7.2) 
RPMI (Sigma, Chem. Co.) 1 pack 
HEPES (Sigma Chem. Co.) 125mM 
L-Glutamine (Sigma Chem. Co.) 4mM 
Sodium Bicarbonate 2 g 
Dissolved in 1000 ml of TDW and filtered through 0.22^ 1 
membrane 
(ii) Complete RPMI-1640 medium 
RPMI (1640) 
Antibiotic/Antimycotic 
PCS (Sigma) 
(iii) Supplement 
Glucose 
Sodium pyruvate 
(Sigma Chem. Co.) 
P-mercaptoethanol 
(Sigma Chem. Co.) 
100 U penicillin/ml, 
100 |ig/ml Streptomycin 
10% 
125}il / 25ml 
2.5% 
lOmM 
1: 5x10^ 
(iv) Scintillation fluid 
PPO (Spectrochem, India) 8 gm/Liter of 
POPOP (SRL, India) 200mg /ILiter of 
Methoxy ethanol Toluene (sulphur free) 
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5. Immunoelectroblotting 
(i) Blotting Buffer 
Tris 25 mM 
Glycine 2 M 
SDS (Sigma) 1% 
Dissolve Tris & Glycine. Then made up to 1000 ml with TDW 
Add SDS & dissolve gently to avoid any frothing. 
(ii) Tris buffered saline (pH 7.4) 
(iii) 
(iv) 
(V) 
(vi) 
Tris 
NaCl 
TDW 
TBS-T-20 (wash buffer) 
TBS 
T-20 
Gelatin (Sigma) 
TBS-Gelatin-T-20 
TBS 
Gelatin 
T-20 
Substrate solution 
TBS 
DAB (Sigma) 
H2O2 
10 mM 
1.5 M 
up to 100 ml 
10 mM 
0.05% 
3 % (in O.IM TBS) 
10 mM 
3% 
0.05% 
10 mM 
30% 
38% 
6. Alkaline gel electrophoresis 
Sodium Sarcosinate (Sigma) 1%) 
NaCl 2.5 M 
Na2-EDTA 100 mM 
Tris 10 mM 
Triton X-100 (Sigma) 1 % 
Ethidium Bromide (Sigma) 0.002% 
Agarose (Low melting)(Sigma) 0.5% 
Agarose (High melting) 0.8%) 
(SRL, India) 
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